var title_f30_52_31552="Stepping response";
var content_f30_52_31552=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infantile stepping response",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 561px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The stepping response can be obtained in infants greater than 32 weeks conceptional age. It is elicited by holding the infant in a vertical position with his or her feet in contact with a flat surface. This initiates a slow alternate stepping action of flexion and extension of the legs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_52_31552=[""].join("\n");
var outline_f30_52_31552=null;
var title_f30_52_31553="Subungual onychomycosis";
var content_f30_52_31553=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Distal subungual onychomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_52_31553=[""].join("\n");
var outline_f30_52_31553=null;
var title_f30_52_31554="Patient information: Weight loss treatments (The Basics)";
var content_f30_52_31554=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15486\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/3/3125\">",
"         Your body mass index (BMI)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/53/3923\">",
"         Patient information: Health risks of obesity (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/30/23010\">",
"         Patient information: My child is overweight (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/37/9811\">",
"         Patient information: Weight loss surgery (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/5/33876\">",
"         Patient information: Weight loss treatments (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Weight loss treatments (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/weight-loss-treatments-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H537472418\">",
"      <span class=\"h1\">",
"       How do I know if I am overweight and by how much?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors use a special measure called &ldquo;body mass index,&rdquo; or BMI, to decide who is underweight, normal weight, or overweight. Your BMI will tell you whether your weight is appropriate for your height (",
"      <a class=\"graphic graphic_figure graphicRef62886 \" href=\"mobipreview.htm?3/3/3125\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        If your BMI is between 25 and 29.9, you are overweight.",
"       </li>",
"       <li>",
"        If your BMI is 30 or greater, you are obese.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H537472425\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are overweight or obese, see your doctor or nurse. He or she might have suggestions on ways to lose weight.",
"     </p>",
"     <p>",
"      Obese people are more likely than people of normal weight to get diabetes, heart disease, cancer, and lots of other health problems. People who are obese also live less time than people of normal weight. That&rsquo;s why it&rsquo;s important to try to keep your weight in the normal range.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H537472432\">",
"      <span class=\"h1\">",
"       What&rsquo;s the best way to lose weight on my own?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To lose weight, you have to eat less or move more. Doing both is even better. People try to make weight loss more complicated than that, but it really isn&rsquo;t.",
"     </p>",
"     <p>",
"      Studies have compared different diets such as the Atkins diet, the Zone diet, and the Weight Watchers diet. No single diet turns out to be better than any other. Any diet that reduces the number of calories you eat can help you lose weight &mdash; as long as you stick with it.",
"     </p>",
"     <p>",
"      Physical activity works the same way. You can walk, dance, garden, or even just move your arms while sitting. What&rsquo;s important is that you increase the number of calories you burn by moving more. And you have to keep doing the extra activity.",
"     </p>",
"     <p>",
"      If you go on a diet for a short time, or increase your activity for a while, you might lose weight. But you will regain the weight if you go back to your old habits. Weight loss is about changing your habits for good.",
"     </p>",
"     <p>",
"      The best way to start is to make small changes and stick with them. Then, little by little, you can add new changes that you also stick with.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H537472439\">",
"      <span class=\"h1\">",
"       Are there medical treatments that can help me lose weight?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are medicines and surgery to help with weight loss. But those treatments are only for people with extreme weight problems who have not been able to lose weight through diet and exercise. What&rsquo;s more, weight loss treatments do not take the place of diet and exercise. People who have those treatments must also change how they eat and how active they are.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H537472446\">",
"      <span class=\"h1\">",
"       How do weight loss medicines work?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Weight loss",
"      <strong>",
"       medicines",
"      </strong>",
"      work by reducing your appetite or by changing how you absorb food. They are appropriate only for people who:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have a BMI of 30 or greater; or",
"       </li>",
"       <li>",
"        Have a BMI between 27 and 30 and also have medical problems, such as diabetes, heart disease, or high blood pressure",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H537472453\">",
"      <span class=\"h1\">",
"       How does weight loss surgery work?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Weight loss",
"      <strong>",
"       surgery",
"      </strong>",
"      works by making your stomach smaller. Some types of surgery also change the path food takes through your gut so that fewer calories and nutrients get absorbed. Weight loss surgery is appropriate only for people who:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have a BMI greater than 40; or",
"       </li>",
"       <li>",
"        Have a BMI between 35 and 40 and also have medical problems, such as diabetes, heart disease, or high blood pressure",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H537472460\">",
"      <span class=\"h1\">",
"       How do I decide if weight loss treatment is right for me?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your doctor suggests weight loss treatment, ask these questions:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         About how much weight can I expect to lose and how long will that take?",
"        </strong>",
"        Many people are surprised to learn that even with surgery, most people never become thin.",
"       </li>",
"       <li>",
"        <strong>",
"         What are the risks of treatment for someone like me?",
"        </strong>",
"        Medicines can have side effects. Surgery can lead to infections, bleeding, the need for other operations, and even death. To reduce the risk of these problems, make sure your surgeon is very experienced and that you are treated at a certified &ldquo;Center of Excellence.&rdquo;",
"       </li>",
"       <li>",
"        <strong>",
"         What changes will I need to make to my diet and lifestyle?",
"        </strong>",
"        Weight loss treatments are not &ldquo;short-cuts&rdquo; that get you out of making lifestyle changes. People getting treated must also change to how they eat and how active they are. No weight loss treatment works on its own. Sometimes people can get surgery only after they prove they can make lifestyle changes&mdash;by losing some weight on their own.",
"       </li>",
"       <li>",
"        <strong>",
"         Will I be able to process food normally?",
"        </strong>",
"        Some types of surgery leave people unable to get all the nutrients they need from food. People who have this problem must take vitamin and mineral supplements for the rest of their lives.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H537472467\">",
"      <span class=\"h1\">",
"       Can I try herbal or non-prescription medicines to lose weight?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some herbal weight loss medicines are unsafe. Check with your doctor or pharmacist before you take any herbal weight loss medicines. There is also a non-prescription version of a medicine doctors prescribe. This medicine is called",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/8/25732?source=see_link\">",
"       orlistat",
"      </a>",
"      (sold as Alli&reg;). It is probably safe to try. But it can cause unwanted side effects, such as cramps, burping, and gas.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H537472474\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/30/23010?source=see_link\">",
"       Patient information: My child is overweight (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/53/3923?source=see_link\">",
"       Patient information: Health risks of obesity (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33876?source=see_link\">",
"       Patient information: Weight loss treatments (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/37/9811?source=see_link\">",
"       Patient information: Weight loss surgery (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/52/31554?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15486 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-17F8E0A872-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_52_31554=[""].join("\n");
var outline_f30_52_31554=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H537472418\">",
"      How do I know if I am overweight and by how much?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H537472425\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H537472432\">",
"      What&rsquo;s the best way to lose weight on my own?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H537472439\">",
"      Are there medical treatments that can help me lose weight?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H537472446\">",
"      How do weight loss medicines work?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H537472453\">",
"      How does weight loss surgery work?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H537472460\">",
"      How do I decide if weight loss treatment is right for me?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H537472467\">",
"      Can I try herbal or non-prescription medicines to lose weight?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H537472474\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15486\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/3/3125\">",
"      Your body mass index (BMI)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/53/3923?source=related_link\">",
"      Patient information: Health risks of obesity (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/30/23010?source=related_link\">",
"      Patient information: My child is overweight (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/37/9811?source=related_link\">",
"      Patient information: Weight loss surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33876?source=related_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_52_31555="Echocardiogram apical 4-chamber with contrast showing dilated RV";
var content_f30_52_31555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echocardiogram apical 4-chamber with and without saline contrast showing enlargement of the right heart chambers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A: Apical four-chamber view from a patient with primary pulmonary hypertension associated with tricuspid regurgitation. There is a large apex-forming right ventricle (RV), large right atrium (RA), and small left ventricle (LV) and left atrium (LA).",
"    <br>",
"     Panel B: Agitated saline contrast is injected intravenously and results in RA and RV opacification; four bubbles are seen in the LV (arrow), possibly due to right-to-left flow across a patent foramen ovale.",
"     <br>",
"      Panel C: Apical four chamber view from a patient with a large left-to-right shunt due to an atrial septal defect (ASD). The RV is apex-forming but the RV and RA are not as large as in panel A.",
"      <br>",
"       Panel D: Contrast is injected intravenously and a few bubbles are seen in the LV; more importantly, there is a prominent negative contrast (nc) effect due to opacified atrial blood.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_52_31555=[""].join("\n");
var outline_f30_52_31555=null;
var title_f30_52_31556="Sublay technique";
var content_f30_52_31556=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Sublay technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 593px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This diagram demonstrates the repair of an abdominal hernia using the sublay technique.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_52_31556=[""].join("\n");
var outline_f30_52_31556=null;
var title_f30_52_31557="Edetate calcium disodium (calcium EDTA): Pediatric drug information";
var content_f30_52_31557=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Edetate calcium disodium (calcium EDTA): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?12/27/12726?source=see_link\">",
"    see \"Edetate calcium disodium (calcium EDTA): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/17/276?source=see_link\">",
"    see \"Edetate calcium disodium (calcium EDTA): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Calcium Disodium Versenate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Lead Toxicity",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Chelating Agent, Parenteral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/27/12726?source=see_link\">",
"      see \"Edetate calcium disodium (calcium EDTA): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Several regimens have been recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Diagnosis of lead poisoning: Mobilization test (not recommended by AAP guidelines): I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose, (maximum dose: 1 g) as a single dose or divided into 2 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Urine is collected for 24 hours after first EDTA dose and analyzed for lead content; if the ratio of mcg of lead in urine to mg calcium EDTA given is &gt;1, then test is considered positive; for convenience, an 8-hour urine collection may be done after a single 50 mg/kg I.M. (maximum dose: 1 g) or 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     I.V. dose; a positive test occurs if the ratio of lead excretion to mg calcium EDTA &gt;0.5-0.6.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of lead poisoning: Children and Adults (each regimen is specific for route):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Symptoms of lead encephalopathy and/or blood lead level &gt;70 mcg/dL: Treat 5 days; give in conjunction with dimercaprol; wait a minimum of 2 days with no treatment before considering a repeat course:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 50 mg/kg/day as 24-hour continuous I.V. infusion",
"     <b>",
"      or",
"     </b>",
"     1-1.5 g/m",
"     <sup>",
"      2",
"     </sup>",
"     I.V. as either an 8- to 24-hour infusion or divided into 2 doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Symptomatic lead poisoning",
"     <b>",
"      without",
"     </b>",
"     encephalopathy",
"     <b>",
"      or",
"     </b>",
"     asymptomatic with blood lead level &gt;70 mcg/dL: Treat 3-5 days; treatment with dimercaprol is recommended until the blood lead level concentration &lt;50 mcg/dL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: 167 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 1 g/m",
"     <sup>",
"      2",
"     </sup>",
"     as an 8- to 24-hour infusion or divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Asymptomatic",
"     <b>",
"      children",
"     </b>",
"     with blood lead level 45-69 mcg/dL: I.V.: 25 mg/kg/day for 5 days as an 8- to 24-hour infusion or divided into 2 doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depending upon the blood lead level, additional courses may be necessary; repeat at least 2-4 days and preferably 2-4 weeks apart",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults with lead nephropathy: An alternative dosing regimen reflecting the reduction in renal clearance is based upon the serum creatinine (adapted from Morgan, 1975; see table):",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Alternative Dosing I.V. Regimen for Adults With Lead Nephropathy",
"     </caption>",
"     <col align=\"center\" width=\"120\">",
"     </col>",
"     <col width=\"300\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Serum Creatinine",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/dL)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Ca EDTA Dosage",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"top\">",
"      <tr>",
"       <td align=\"left\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Adapted from Morgan, 1975.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Repeat these regimens monthly until lead excretion is reduced toward normal.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;2-3",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         Reduce recommended dosage by 50%",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;3-4",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         Reduce recommended dosage by 50% and administer every other day",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;4",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         Reduce recommended dosage by 50% and administer once weekly",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F164129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Calcium Disodium Versenate&reg;: 200 mg/mL (2.5 mL, 5 mL [DSC])",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F164114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intermittent I.V. infusion: Administer the dose I.V. over at least 1 hour in asymptomatic patients, 2 hours in symptomatic patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Single daily I.V. continuous infusion: Dilute to 2-4 mg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS and infuse over at least 8 hours, usually over 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M. injection: To minimize pain at the injection site, 1.67 mL of 2% procaine may be added to 5 mL calcium EDTA, resulting in 150 mg/mL concentration with 0.5% procaine (stable 3 months; Nahata, 1997)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F164157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, Ringer's injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Lidocaine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dilute with NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W; physically incompatible with D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR; do not mix in the same syringe with dimercaprol",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute and chronic lead poisoning; also used as an aid in the diagnosis of lead poisoning",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2932700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       To avoid potentially serious errors, the abbreviation &ldquo;EDTA&rdquo; should",
"       <b>",
"        never",
"       </b>",
"       be used.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"       Edetate CALCIUM disodium (CaEDTA) may be confused with edetate disodium (Na",
"       <sub>",
"        2",
"       </sub>",
"       EDTA) (not commercially available in the U.S. or Canada). CDC recommends that edetate disodium should",
"       <b>",
"        never",
"       </b>",
"       be used for chelation therapy in children. Fatal hypocalcemia may result if edetate disodium is used for chelation therapy instead of edetate calcium disodium. ISMP recommends confirming the diagnosis to help distinguish between the two drugs prior to dispensing and/or administering either drug.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"       Edetate CALCIUM disodium may be confused with etomidate",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F164156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, ECG changes, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, fatigue, fever, headache, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Cheilosis, dermatitis, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercalcemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, GI upset, nausea, thirst (excessive), vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, bone marrow suppression (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase decreased, liver function test increased (mild)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at injection site (I.M. injection), thrombophlebitis (I.V. infusion when concentration &gt;5 mg/mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia, numbness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Lacrimation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Glucosuria, microscopic hematuria, nephrosis, nephrotoxicity, proteinuria, renal tubular necrosis, urinary frequency/urgency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion, sneezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Iron, magnesium, and/or zinc deficiency (with chronic therapy)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to edetate calcium disodium or any component; active renal disease, anuria, hepatitis",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal tubular necrosis and fatal nephrosis may occur, especially with high doses; establish urine flow prior to administration",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with lead encephalopathy and cerebral edema may experience a lethal increase in intracranial pressure following I.V. infusion of edetate CALCIUM EDTA",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; avoid rapid I.V. infusion, particularly in the management of lead encephalopathy; I.M. administration is the preferred route in these patients, if the I.V. route is necessary, infuse slowly (over at least 3 hours)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; do not exceed recommended daily dose",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; if anuria, increasing proteinuria, or hematuria occurs during therapy, discontinue calcium EDTA.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Edetate CALCIUM Disodium may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F164125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6151785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies; there are no well controlled studies of edetate CALCIUM disodium in pregnant women. Lead is known to cross the placenta in amounts related to maternal plasma levels.  Prenatal lead exposure may be associated with adverse events such as spontaneous abortion, preterm delivery, decreased birth weight, and impaired neurodevelopment.  Some adverse outcomes may occur with maternal blood lead levels &lt;10 mcg/dL.  In addition, pregnant women exposed to lead may have an increased risk of gestational hypertension. Consider chelation therapy in pregnant women with confirmed blood lead levels &ge;45 mcg/dL (pregnant women with blood lead levels &ge;70 mcg/dL should be considered for chelation regardless of trimester); consultation with experts in lead poisoning and high-risk pregnancy is recommended.  Encephalopathic pregnant women should be chelated regardless of trimester (CDC, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1058250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     BUN, serum creatinine, urinalysis, fluid balance, ECG, blood and urine lead concentrations",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium is displaced by divalent and trivalent heavy metals, forming a nonionizing soluble complex that is excreted in the urine",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1058257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of chelation with I.V. administration: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum excretion of chelated lead with I.V. administration: 24-48 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M., SubQ: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Into extracellular fluid; minimal CSF penetration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, plasma:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Rapid in urine as metal chelates or unchanged drug",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Treatment Guidelines for Lead Exposure in Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1995, 96(1 Pt 1):155-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/52/31557/abstract-text/7596706/pubmed\" id=\"7596706\" target=\"_blank\">",
"        7596706",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gracia RC and Snodgrass WR, \"Lead Toxicity and Chelation Therapy,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2007, 64(1):45-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/52/31557/abstract-text/17189579/pubmed\" id=\"17189579\" target=\"_blank\">",
"        17189579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan JM, \"Chelation Therapy in Lead Nephropathy,\"",
"      <i>",
"       South Med J",
"      </i>",
"      , 1975, 68(8):1001-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/52/31557/abstract-text/125923/pubmed\" id=\"125923\" target=\"_blank\">",
"        125923",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nahata MC and Hipple TF,",
"      <i>",
"       Pediatric Drug Formulations",
"      </i>",
"      , 3rd ed, Cincinnati, OH: Harvey Whitney Books Co, 1997.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13264 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-2FE80B8408-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_52_31557=[""].join("\n");
var outline_f30_52_31557=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708725\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164143\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058251\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058244\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164129\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164114\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058255\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164157\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058248\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058254\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2932700\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164156\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058259\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058243\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058242\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299251\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220072\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164125\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6151785\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058250\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058241\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058257\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058258\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13264\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13264|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/27/12726?source=related_link\">",
"      Edetate calcium disodium (calcium EDTA): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/17/276?source=related_link\">",
"      Edetate calcium disodium (calcium EDTA): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_52_31558="Assessment of amniotic fluid volume";
var content_f30_52_31558=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assessment of amniotic fluid volume",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/52/31558/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/52/31558/contributors\">",
"     Everett Magann, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/52/31558/contributors\">",
"     Michael G Ross, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/52/31558/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/52/31558/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/52/31558/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/52/31558/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/52/31558/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/52/31558/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amniotic fluid volume (AFV) should be assessed either qualitatively or quantitatively at every antenatal ultrasound examination. There are a variety of reasons for this recommendation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced or absent amniotic fluid is suggestive, but not diagnostic, of premature rupture of membranes",
"     </li>",
"     <li>",
"      Fetal congenital anomalies (eg, gastrointestinal or urinary tract obstruction), chromosomal abnormalities (eg, trisomy 18), and fetal growth restriction can be associated with abnormalities of amniotic fluid volume",
"     </li>",
"     <li>",
"      Abnormal amniotic fluid volume may be associated with an increased risk of a variety of adverse perinatal outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/1-3\">",
"       1-3",
"      </a>",
"      ]. Thus, assessment of amniotic fluid volume is one of several parameters used in antenatal fetal surveillance (eg, as part of the biophysical profile or in conjunction with a nonstress test). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11928?source=see_link\">",
"       \"The fetal biophysical profile\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To clearly identify abnormal amniotic fluid volumes, normal amniotic fluid volumes must be defined across gestation as a reference for characterizing volumes that deviate from normal (",
"    <a class=\"graphic graphic_figure graphicRef59704 \" href=\"mobipreview.htm?35/11/36030\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/888?source=see_link\">",
"     \"Physiology of amniotic fluid volume regulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sonographic assessment of amniotic fluid volume will be reviewed here. Specific disorders of amniotic fluid volume, such as oligohydramnios and polyhydramnios, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14233?source=see_link\">",
"     \"Oligohydramnios\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4808?source=see_link\">",
"     \"Polyhydramnios\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF TOTAL AFV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most accurate methods for determining total amniotic fluid volume are direct measurement at the time of hysterotomy and dye-dilution techniques. However, the clinical application of these techniques is problematic. Direct measurement of amniotic fluid is not an option for ongoing fetal assessment during pregnancy, while dye-dilution techniques are cumbersome, invasive, and require specialized technical skills and laboratory support. Therefore, use of these techniques is generally restricted to research studies, where they represent the reference for evaluating the accuracy of ultrasound measurements of AFV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ULTRASOUND ESTIMATION OF AFV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound examination is the only practical clinical method of assessing amniotic fluid volume. Five ultrasound methods have been used; each has limitations in the detection of abnormal amniotic fluid volumes. The most clinically relevant method should be the one which best determines the volume of amniotic fluid associated with adverse outcome rather than one that best calculates volume outside of a 95 percent confidence interval for gestational age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Single deepest pocket technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The single deepest pocket (SDP) measurement refers to the vertical dimension of the largest pocket of amniotic fluid not containing umbilical cord or fetal extremities and measured at a right angle to the uterine contour. The horizontal component of this vertical dimension must be at least 1 cm. The SDP measurement has been interpreted as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oligohydramnios &mdash; depth of 0 to 2 cm",
"     </li>",
"     <li>",
"      Normal &mdash; depth of 2.1 to 8 cm",
"     </li>",
"     <li>",
"      Polyhydramnios &mdash; depth greater than 8 cm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A study including 40 pregnancies compared the SDP to dye-determined amniotic fluid volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/8\">",
"     8",
"    </a>",
"    ]. Ninety-four percent of the normal pregnancies were identified by SDP, but none of the pregnancies with a low dye-determined amniotic fluid volume were detected. Low dye dilution amniotic fluid volume was defined as less than or equal to the volume of fluid at the fifth percentile for gestational age. In another series of 45 pregnancies, the SDP measurement was compared to direct measurement of amniotic fluid volume at cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/9\">",
"     9",
"    </a>",
"    ]. SDP identified only 18 percent of the pregnancies with low amniotic fluid volume. These studies showed that the SDP technique detects fewer pregnancies with low amniotic fluid volume than dye-dilution and direct assessment methods.",
"   </p>",
"   <p>",
"    The SDP technique is most commonly employed as one of the components of the biophysical profile. In this setting, it appears to be useful for the evaluation of pregnancies at risk of an adverse pregnancy outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11928?source=see_link\">",
"     \"The fetal biophysical profile\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Amniotic fluid index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amniotic fluid index (AFI) measurement is calculated by first dividing the uterus into four quadrants using the linea nigra for the right and left divisions and the umbilicus for the upper and lower quadrants. The maximum vertical amniotic fluid pocket diameter in each quadrant not containing cord or fetal extremities is measured in centimeters; the sum of these measurements is the AFI. The AFI can be interpreted according to the following thresholds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oligohydramnios &mdash; 0 to &lt;5 cm",
"     </li>",
"     <li>",
"      Normal &mdash; 5 to 25 cm",
"     </li>",
"     <li>",
"      Polyhydramnios &mdash; greater than 25 cm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, variations in the thresholds used are common. As an example, some centers use an AFI of &le;5 cm (rather than &lt;5 cm) or even less than 6 or 7 cm to define oligohydramnios and an AFI greater than 20 to define polyhydramnios. Currently, there is insufficient evidence to recommend any additional antenatal assessments because of borderline AFI (5.1 to 8 cm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The accuracy and prognostic value of the AFI has been examined in several studies, which have shown that an abnormal test is neither highly accurate nor predictive of adverse outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/1,8,15-18\">",
"     1,8,15-18",
"    </a>",
"    ]. The range of findings is illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of 50 pregnancies compared 13 different ultrasound techniques for measurement of amniotic fluid volume to dye dilution-determined amniotic fluid volume [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/15\">",
"       15",
"      </a>",
"      ]. The AFI was superior to all of the other techniques and concordant with dye-determined volume in 71 percent of cases. However, at low volumes the AFI overestimated dye-determined volumes by 89 percent and at high volumes AFI underestimated dye-determined volumes by 54 percent.",
"     </li>",
"     <li>",
"      A second report compared the AFI to dye-determined amniotic fluid volume in 40 pregnancies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/8\">",
"       8",
"      </a>",
"      ]. The AFI agreed with 78 percent of dye-determined normal volumes; however, only 2 of 21 pregnancies with low dye-determined volumes were identified by the AFI. Similar results were obtained in a series of 57 pregnancies in which AFI identified 87 percent of the dye-determined normal volumes, but only 8.7 percent of the dye-determined low volumes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another analysis of these two techniques in 144 pregnancies used receiver operator characteristic curves to calculate the AFI at which oligohydramnios was not present with 95 percent confidence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/17\">",
"       17",
"      </a>",
"      ]. The authors concluded this value was 30 cm, a value typically considered to represent hydramnios. The sensitivity, specificity, positive, and negative predictive values of AFI &le;5 for oligohydramnios were 5, 98, 80, and 49 percent; these same characteristics for AFI &gt;24 for polyhydramnios were 30, 98, 57, and 93 percent.",
"     </li>",
"     <li>",
"      Lastly, dye-determined amniotic fluid volume was used to evaluate 291 singleton pregnancies with AFI and SDP &lt;3rd and 5th percentiles and &gt;95th and 97th percentiles, adjusted for gestational age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/18\">",
"       18",
"      </a>",
"      ]. The sensitivity of AFI or SDP &lt;3rd and 5th percentile to detect oligohydramnios ranged from 11 to 27 percent, and was 33 to 46 percent for detection of hydramnios. Use of percentiles was no better than fixed cutoffs (eg, AFI &le;5 or &gt;25, SDP &lt;2 or &gt;8 cm) for detecting oligohydramnios and hydramnios.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies show that the ability of AFI to detect abnormal amniotic fluid volume (low or high) is poor because many pregnancies with normal amniotic fluid volume will be falsely characterized as abnormal and a large number with truly abnormal amniotic fluid volumes will be missed.",
"   </p>",
"   <p>",
"    Use of percentiles rather than fixed cut offs to identify low or high amniotic fluid volumes does not improve the accuracy of the method.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Two diameter pocket technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two diameter amniotic fluid pocket is the product of the vertical depth multiplied by the horizontal diameter of the largest pocket of amniotic fluid not containing umbilical cord or extremities (with the transducer held at a right angle to the uterine contour). Results are interpreted as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oligohydramnios &mdash; 0 to 15 cm(2)",
"     </li>",
"     <li>",
"      Normal &mdash; 15.1 to 50 cm(2)",
"     </li>",
"     <li>",
"      Polyhydramnios &mdash; greater than 50 cm(2)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two series that compared the two diameter pocket and dye-determined amniotic fluid volume found the former identified 81 to 94 percent of the dye-determined normal volumes and approximately 60 percent of pregnancies with low volumes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/8,16\">",
"     8,16",
"    </a>",
"    ]. Receiver operator curve analysis showed that for any specific two diameter pocket, the 95 percent confidence range was so wide that ultrasonographic assessment was not a reasonable reflection of actual amniotic fluid volume, and thus was not clinically useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     2 x 1 cm or 2 x 2 cm pocket technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;These methods of amniotic fluid assessment involve identification of at least one pocket of amniotic fluid with minimum dimensions of 2 by 1 cm or 2 by 2 cm measured vertically and horizontally (or horizontally and vertically). The 2 by 1 cm pocket technique is the primary technique used by Manning as one of the five components (amniotic fluid volume) of the biophysical profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11928?source=see_link\">",
"     \"The fetal biophysical profile\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2 by 2 cm pocket is a subsequent innovation; its ability to predict an adverse intrapartum or perinatal outcome is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/19\">",
"     19",
"    </a>",
"    ]. When the 2 by 2 cm pocket technique was compared to a dye-determined amniotic fluid volume in 79 pregnancies, the pocket technique identified 98 percent of pregnancies with normal dye-determined volume, but only 9.5 percent of those with low volumes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Subjective assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subjective assessment of amniotic fluid volume refers to visual interpretation without sonographic measurements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/21\">",
"     21",
"    </a>",
"    ]. The ultrasonographer scans the uterine contents and subsequently reports the amniotic fluid volume as oligohydramnios, normal, or polyhydramnios.",
"   </p>",
"   <p>",
"    One study involving 63 pregnancies compared the subjective assessment of amniotic fluid volume to ultrasound measurement of AFI, the single deepest pocket technique, and the two diameter pocket method in the identification of dye-determined amniotic fluid volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/21\">",
"     21",
"    </a>",
"    ]. The subjective assessment of amniotic fluid volume by an experienced examiner had a similar sensitivity to the other techniques for identifying dye-determined amniotic fluid volumes. The subjective technique and the quantitative ultrasound methods all identified normal volumes well, but determined low and high volumes poorly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COMPARISON OF SONOGRAPHIC METHODS FOR ESTIMATING AFV",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the most clinically relevant method of amniotic fluid assessment should be the one which best determines the volume of amniotic fluid associated with adverse outcome, rather than one that best calculates actual volume or volume outside of a 95 percent confidence interval for gestational age. A systematic review of well-designed randomized trials compared the AFI to the SDP for predicting adverse antepartum, intrapartum, and perinatal outcome and found the AFI was no better than the SDP for predicting an adverse outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/22\">",
"     22",
"    </a>",
"    ]. The AFI diagnosed significantly more cases of oligohydramnios (RR 2.3), which led to significantly more intervention &mdash; induction of labor increased two-fold and cesarean delivery increased 1.5-fold &mdash; without improving perinatal outcome. Both techniques appear to be poor diagnostic tests for identifying pregnancies that will require cesarean delivery for nonreassuring fetal heart rate tracings or neonatal acidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In clinical practice, ultrasound estimation of amniotic fluid volume is used in conjunction with other clinical and sonographic assessments (eg, biophysical profile, nonstress test, ultrasound examination for estimated fetal weight, anatomic survey) to provide useful information for managing complicated pregnancies. Therefore, obstetrical ultrasound examinations should include an assessment of amniotic fluid volume. We suggest subjective assessment of amniotic fluid volume in all ultrasound examinations and use of an objective measure if the subjective assessment is abnormal, in patients at increased risk of pregnancy complications, and in all patients examined in the third trimester.",
"   </p>",
"   <p>",
"    Seemingly, in all but postterm pregnancies, the AFI and SDP (along with the other components of antenatal testing) are equivalent and poor in their prediction of an adverse outcome. Because the AFI will label 2 to 3 times as many women as having oligohydramnios compared with the SDP, this may result in more interventions and inductions of labor and increased maternal and perinatal morbidity without any improvement in neonatal outcome. Although the SDP may be the preferred technique of estimating amniotic fluid volume, the AFI is more commonly utilized in practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     AFV ASSESSMENT IN TWINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of AFV in twin pregnancies, which have a perinatal mortality several-fold higher than singleton pregnancies, is an important part of their overall evaluation. As with singleton pregnancies, normal AFV in diamniotic twin pregnancies has been determined by dye-dilution techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/24\">",
"     24",
"    </a>",
"    ]. The mean AFV in each sac of a twin pregnancy is slightly higher than that of a singleton pregnancy of the same gestational age. However, as discussed above, this method is impractical for clinical use in monitoring twin pregnancies.",
"   </p>",
"   <p>",
"    Three ultrasound techniques have been used to estimate the AFV in diamniotic twin pregnancies. All three methods correlate poorly with dye-determined low or high volumes, in part, because the position of the dividing membrane affects the interpretation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SDP &mdash; The simplest and most frequently used method of AFV assessment is to determine the SDP of each fetus within its own amniotic sac and interpret the results using the SDP criteria described above for singletons. High SDPs have been correlated with abnormal fetal heart rate tracings in labor and an increased frequency of cesarean deliveries for fetal intolerance of labor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Other SDP techniques used to estimate AFV in twins are to locate the dividing membrane and measure the SDP of each twin above and below the fetal diaphragm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/26\">",
"       26",
"      </a>",
"      ], sum the SDP of amniotic fluid in the four quadrants of fluid in each sac surrounding the fetus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/27\">",
"       27",
"      </a>",
"      ], or to measure the SDP of fluid in each of the quadrants the fetus occupies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Subjective evaluation &mdash; A study including 23 twin pregnancies subjectively and objectively evaluated AFV and then compared these results with the dye-determined volume [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/29\">",
"       29",
"      </a>",
"      ]. There were no differences in the accuracy of the subjective versus the objective evaluation of AFV to identify abnormal volumes. Both techniques were equally poor in the identification of the extremes (high and low) of AFV in twin pregnancies.",
"     </li>",
"     <li>",
"      AFI &mdash; The AFI technique is similar to that used in singleton pregnancies. The abdomen is divided into four quadrants, as described above. The single deepest pocket without fetal small parts or cord is determined in each quadrant, without taking the membrane separating the twins into consideration, and the sum of the measurements for the four quadrants is calculated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/30-32\">",
"       30-32",
"      </a>",
"      ]. An AFI of &lt;5 cm is considered oligohydramnios, 5 to 25 cm is considered a normal volume, and &ge;25 cm is considered polyhydramnios; these are the same thresholds used in singleton pregnancies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The summated AFI over-identifies abnormal AFVs as normal when membrane placement is not taken into consideration. In a study of 62 diamniotic twin pregnancies in which the AFV was determined by dye-dilution, the summated AFI identified 90 percent of the twin pairs as having normal fluid volumes; however, 32 percent had an abnormal dye-dilution fluid volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31558/abstract/33\">",
"     33",
"    </a>",
"    ]. Additionally, 10 of the 62 sets of twins had low dye-dilution fluid volume in both sacs, but the summated AFI identified 80 percent of these twins as having a normal AFV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Amniotic fluid volume should be assessed either qualitatively or quantitatively at every antenatal ultrasound examination because abnormalities of amniotic fluid volume are associated with a variety of pregnancy complications. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Actual amniotic fluid volume can be measured directly at the time of operative delivery or by dye-dilution techniques; however, these methods are impractical for clinical management. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Measurement of total AFV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasound techniques used to estimate the adequacy of amniotic fluid volume include the single deepest pocket (SDP), amniotic fluid index (AFI), two diameter pocket, 2 by 1 cm or 2 by 2 cm pocket techniques and subjective assessment. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Ultrasound estimation of AFV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All sonographic methods of amniotic fluid volume are more reliable for identifying normal amniotic fluid volume than abnormal amniotic fluid volume (oligohydramnios and polyhydramnios); they all detect abnormal amniotic fluid volume poorly. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Ultrasound estimation of AFV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In clinical practice, ultrasound estimation of amniotic fluid volume is used in conjunction with other clinical and sonographic assessments (eg, biophysical profile, nonstress test, ultrasound examination for estimated fetal weight, anatomic survey) to provide useful information for managing complicated pregnancies.",
"      <br/>",
"      <br/>",
"      We suggest subjective assessment of amniotic fluid volume in all antepartum ultrasound examinations and use of an objective measure if the subjective assessment is abnormal, in patients at increased risk of pregnancy complications, and in all patients examined in the third trimester. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Comparison of sonographic methods for estimating AFV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The single deepest pocket (SDP) and the AFI method are equivalent in their prediction of adverse outcomes and actual oligohydramnios and polyhydramnios in singleton pregnancies, but use of the AFI increases the number of labor inductions and cesarean deliveries without any improvement in perinatal outcome. This favors use of the SDP for amniotic fluid volume assessment. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Comparison of sonographic methods for estimating AFV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasound estimates of amniotic fluid volume in twin pregnancies correlate poorly with dye-determined low or high volumes. Membrane placement must be taken into consideration in the evaluation of the amniotic fluid in diamniotic twin pregnancies. The SDP technique of each sac is the most frequently used method to estimate the amniotic fluid volume of each fetus. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'AFV assessment in twins'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/1\">",
"      Ott WJ. Reevaluation of the relationship between amniotic fluid volume and perinatal outcome. Am J Obstet Gynecol 2005; 192:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/2\">",
"      Locatelli A, Zagarella A, Toso L, et al. Serial assessment of amniotic fluid index in uncomplicated term pregnancies: prognostic value of amniotic fluid reduction. J Matern Fetal Neonatal Med 2004; 15:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/3\">",
"      Chauhan SP, Sanderson M, Hendrix NW, et al. Perinatal outcome and amniotic fluid index in the antepartum and intrapartum periods: A meta-analysis. Am J Obstet Gynecol 1999; 181:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/4\">",
"      Brace RA, Wolf EJ. Normal amniotic fluid volume changes throughout pregnancy. Am J Obstet Gynecol 1989; 161:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/5\">",
"      Magann EF, Bass JD, Chauhan SP, et al. Amniotic fluid volume in normal singleton pregnancies. Obstet Gynecol 1997; 90:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/6\">",
"      Queenan JT, Thompson W, Whitfield CR, Shah SI. Amniotic fluid volumes in normal pregnancies. Am J Obstet Gynecol 1972; 114:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/7\">",
"      Chamberlain PF, Manning FA, Morrison I, et al. Ultrasound evaluation of amniotic fluid volume. I. The relationship of marginal and decreased amniotic fluid volumes to perinatal outcome. Am J Obstet Gynecol 1984; 150:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/8\">",
"      Magann EF, Nolan TE, Hess LW, et al. Measurement of amniotic fluid volume: accuracy of ultrasonography techniques. Am J Obstet Gynecol 1992; 167:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/9\">",
"      Horsager R, Nathan L, Leveno KJ. Correlation of measured amniotic fluid volume and sonographic predictions of oligohydramnios. Obstet Gynecol 1994; 83:955.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Antepartum fetal surveillance. ACOG practice bulletin #9. ACOG, Washington, DC 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/11\">",
"      Magann EF, Doherty DA, Field K, et al. Biophysical profile with amniotic fluid volume assessments. Obstet Gynecol 2004; 104:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/12\">",
"      Rutherford SE, Phelan JP, Smith CV, Jacobs N. The four-quadrant assessment of amniotic fluid volume: an adjunct to antepartum fetal heart rate testing. Obstet Gynecol 1987; 70:353.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical Management Guidelines for Obstetrician-Gynecologists, Number 55, September 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/14\">",
"      Magann EF, Chauhan SP, Hitt WC, et al. Borderline or marginal amniotic fluid index and peripartum outcomes: a review of the literature. J Ultrasound Med 2011; 30:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/15\">",
"      Dildy GA 3rd, Lira N, Moise KJ Jr, et al. Amniotic fluid volume assessment: comparison of ultrasonographic estimates versus direct measurements with a dye-dilution technique in human pregnancy. Am J Obstet Gynecol 1992; 167:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/16\">",
"      Magann EF, Morton ML, Nolan TE, et al. Comparative efficacy of two sonographic measurements for the detection of aberrations in the amniotic fluid volume and the effect of amniotic fluid volume on pregnancy outcome. Obstet Gynecol 1994; 83:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/17\">",
"      Chauhan SP, Magann EF, Morrison JC, et al. Ultrasonographic assessment of amniotic fluid does not reflect actual amniotic fluid volume. Am J Obstet Gynecol 1997; 177:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/18\">",
"      Magann EF, Doherty DA, Chauhan SP, et al. How well do the amniotic fluid index and single deepest pocket indices (below the 3rd and 5th and above the 95th and 97th percentiles) predict oligohydramnios and hydramnios? Am J Obstet Gynecol 2004; 190:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/19\">",
"      Magann EF, Isler CM, Chauhan SP, Martin JN Jr. Amniotic fluid volume estimation and the biophysical profile: a confusion of criteria. Obstet Gynecol 2000; 96:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/20\">",
"      Magann EF, Nevils BG, Chauhan SP, et al. Low amniotic fluid volume is poorly identified in singleton and twin pregnancies using the 2 x 2 cm pocket technique of the biophysical profile. South Med J 1999; 92:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/21\">",
"      Magann EF, Perry KG Jr, Chauhan SP, et al. The accuracy of ultrasound evaluation of amniotic fluid volume in singleton pregnancies: the effect of operator experience and ultrasound interpretative technique. J Clin Ultrasound 1997; 25:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/22\">",
"      Nabhan AF, Abdelmoula YA. Amniotic fluid index versus single deepest vertical pocket as a screening test for preventing adverse pregnancy outcome. Cochrane Database Syst Rev 2008; :CD006593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/23\">",
"      Chauhan SP, Doherty DD, Magann EF, et al. Amniotic fluid index vs single deepest pocket technique during modified biophysical profile: a randomized clinical trial. Am J Obstet Gynecol 2004; 191:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/24\">",
"      Magann EF, Whitworth NS, Bass JD, et al. Amniotic fluid volume of third-trimester diamniotic twin pregnancies. Obstet Gynecol 1995; 85:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/25\">",
"      Magann EF, Doherty DA, Ennen CS, et al. The ultrasound estimation of amniotic fluid volume in diamniotic twin pregnancies and prediction of peripartum outcomes. Am J Obstet Gynecol 2007; 196:570.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/26\">",
"      Gerson A, Free SM Jr, Russino J, et al. Amniotic fluid index in twin gestation. Ultrasound Obstet Gynecol 1997; 10:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/27\">",
"      Hill LM, Krohn M, Lazebnik N, et al. The amniotic fluid index in normal twin pregnancies. Am J Obstet Gynecol 2000; 182:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/28\">",
"      Magann EF, Chauhan SP, Martin JN Jr, et al. Ultrasonic assessment of the amniotic fluid volume in diamniotic twins. J Soc Gynecol Investig 1995; 2:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/29\">",
"      Magann EF, Chauhan SP, Whitworth NS, et al. Determination of amniotic fluid volume in twin pregnancies: ultrasonographic evaluation versus operator estimation. Am J Obstet Gynecol 2000; 182:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/30\">",
"      Watson WJ, Harlass FE, Menard MK, et al. Sonographic assessment of amniotic fluid in normal twin pregnancy. Am J Perinatol 1995; 12:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/31\">",
"      Chau AC, Kjos SL, Kovacs BW. Ultrasonographic measurement of amniotic fluid volume in normal diamniotic twin pregnancies. Am J Obstet Gynecol 1996; 174:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/32\">",
"      Porter TF, Dildy GA, Blanchard JR, et al. Normal values for amniotic fluid index during uncomplicated twin pregnancy. Obstet Gynecol 1996; 87:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31558/abstract/33\">",
"      Magann EF, Chauhan SP, Whitworth NS, et al. The accuracy of the summated amniotic fluid index in evaluating amniotic fluid volume in twin pregnancies. Am J Obstet Gynecol 1997; 177:1041.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 462 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-158A9A2F60-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_52_31558=[""].join("\n");
var outline_f30_52_31558=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEASUREMENT OF TOTAL AFV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ULTRASOUND ESTIMATION OF AFV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Single deepest pocket technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Amniotic fluid index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Two diameter pocket technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      2 x 1 cm or 2 x 2 cm pocket technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Subjective assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COMPARISON OF SONOGRAPHIC METHODS FOR ESTIMATING AFV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      AFV ASSESSMENT IN TWINS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/462\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/462|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/11/36030\" title=\"figure 1\">",
"      Normal amniotic fluid volume",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14233?source=related_link\">",
"      Oligohydramnios",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/888?source=related_link\">",
"      Physiology of amniotic fluid volume regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4808?source=related_link\">",
"      Polyhydramnios",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11928?source=related_link\">",
"      The fetal biophysical profile",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_52_31559="Androgenetic alopecia vertex";
var content_f30_52_31559=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Androgenetic alopecia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hair loss on the vertex of the scalp in a man with androgenetic alopecia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_52_31559=[""].join("\n");
var outline_f30_52_31559=null;
var title_f30_52_31560="Diclofenac (systemic): Pediatric drug information";
var content_f30_52_31560=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diclofenac (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?8/43/8890?source=see_link\">",
"    see \"Diclofenac (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/32/20998?source=see_link\">",
"    see \"Diclofenac (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8016815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8016831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cambia&trade;;",
"     </li>",
"     <li>",
"      Cataflam&reg;;",
"     </li>",
"     <li>",
"      Voltaren&reg;-XR;",
"     </li>",
"     <li>",
"      Zipsor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8016832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Diclo Rapide&reg;;",
"     </li>",
"     <li>",
"      Apo-Diclo&reg;;",
"     </li>",
"     <li>",
"      Apo-Diclo&reg; SR&reg;;",
"     </li>",
"     <li>",
"      Ava-Diclofenac;",
"     </li>",
"     <li>",
"      Ava-Diclofenac SR;",
"     </li>",
"     <li>",
"      Cambia&reg;;",
"     </li>",
"     <li>",
"      Cataflam&reg;;",
"     </li>",
"     <li>",
"      Diclofenac ECT;",
"     </li>",
"     <li>",
"      Diclofenac Sodium;",
"     </li>",
"     <li>",
"      Diclofenac Sodium SR;",
"     </li>",
"     <li>",
"      Diclofenac SR;",
"     </li>",
"     <li>",
"      Dom-Diclofenac;",
"     </li>",
"     <li>",
"      Dom-Diclofenac SR;",
"     </li>",
"     <li>",
"      NTP-Diclofenac;",
"     </li>",
"     <li>",
"      NTP-Diclofenac SR;",
"     </li>",
"     <li>",
"      Nu-Diclo;",
"     </li>",
"     <li>",
"      Nu-Diclo-SR;",
"     </li>",
"     <li>",
"      PMS-Diclofenac;",
"     </li>",
"     <li>",
"      PMS-Diclofenac SR;",
"     </li>",
"     <li>",
"      PMS-Diclofenac-K;",
"     </li>",
"     <li>",
"      PRO-Diclo-Rapide;",
"     </li>",
"     <li>",
"      Sandoz-Diclofenac;",
"     </li>",
"     <li>",
"      Sandoz-Diclofenac Rapide;",
"     </li>",
"     <li>",
"      Sandoz-Diclofenac SR;",
"     </li>",
"     <li>",
"      Teva-Diclofenac;",
"     </li>",
"     <li>",
"      Teva-Diclofenac K;",
"     </li>",
"     <li>",
"      Teva-Diclofenac SR;",
"     </li>",
"     <li>",
"      Voltaren Rapide&reg;;",
"     </li>",
"     <li>",
"      Voltaren SR&reg;;",
"     </li>",
"     <li>",
"      Voltaren&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10885590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Non-narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10886046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/43/8890?source=see_link\">",
"      see \"Diclofenac (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Different  oral formulations are not bioequivalent; do not interchange products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents &lt;18 years:",
"     <b>",
"      Juvenile idiopathic arthritis:",
"     </b>",
"     Limited data available: Oral: Immediate release tablet: 2-3 mg/kg/day divided 2-4 times/day; maximum daily dose: 200 mg/",
"     <b>",
"      day",
"     </b>",
"     (Haapasaari, 1983; Hashkes, 2005 )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adolescents &ge;18 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Analgesia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immediate release capsule: 25 mg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immediate release tablet: Adults: Initial: 50 mg 3 times/day [maximum dose: 150 mg/day; may administer 100 mg loading dose, followed by 50 mg every 8 hours; initial maximum daily dose (day 1): 200 mg/day; maximum dose day 2 and thereafter: 150 mg/day]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Ankylosing spondylitis:",
"     </b>",
"     Adults: Oral: Delayed release tablet: 100-125 mg/day in 4-5 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Migraine:",
"     </b>",
"     Oral: Oral solution: 50 mg (one packet) as a single dose at the time of migraine onset; safety and efficacy of a second dose have not been established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Osteoarthritis:",
"     </b>",
"     Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immediate release tablet: 150-200 mg/day in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Delayed release tablet: 150-200 mg/day in 2-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extended release tablet: 100 mg/day; may increase dose to 200 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Primary dysmenorrhea:",
"     </b>",
"     Adults: Oral: Immediate release tablet: Initial: 50 mg 3 times/day (maximum dose: 150 mg/day); may administer 100 mg loading dose, followed by 50 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immediate release tablet: 150-200 mg/day in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Delayed release tablet: 150-200 mg/day in 2-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extended release tablet: 100 mg/day; may increase dose to 200 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Not recommended in patients with advanced renal disease or significant renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     May require dosage adjustment; use oral solution only if benefits outweigh risks.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8017239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid filled, oral, as potassium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zipsor&reg;: 25 mg [contains gelatin]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral, as potassium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cambia&trade;: 50 mg/packet (1s) [contains phenylalanine 25 mg/packet; anise-mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as potassium: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cataflam&reg;: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, enteric coated, oral, as sodium: 25 mg, 50 mg, 75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as sodium: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Voltaren&reg;-XR: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8016834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes capsule, oral solution",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8016830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cambia&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM169077.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM169077.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cataflam&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM135935.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM135935.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Voltaren&reg;-XR:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089822.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089822.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Zipsor&reg;:  file://zipsor.com/patient/html_pages/medication_guide.html",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10886047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with milk or food to decrease GI upset; take with full glass of water to enhance absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delayed or extended release dosage form: Do not chew or crush delayed release or extended release tablets, swallow whole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution: Empty contents of packet into 1-2 ounces (30-60 mL) of water (do not use other liquids); mix well and administer right away. Food may reduce effectiveness.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10885928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule, oral solution: Store at 25&deg;C (77&deg;F); excursions permitted from 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Store at &le;30&deg;C (86&deg;F); protect from moisture; dispense in tight container",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10885885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: Relief of mild to moderate acute pain (FDA approved in ages &ge;18 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release tablet: Relief of mild to moderate pain; primary dysmenorrhea; acute and chronic treatment of rheumatoid arthritis and osteoarthritis (all indications: FDA approved in adults); has also been used for juvenile idiopathic arthritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delayed release tablet: Acute and chronic treatment of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release tablet: Chronic treatment of osteoarthritis and rheumatoid arthritis (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution: Treatment of acute migraine with or without aura (FDA approved in ages &ge;18 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8016829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Diclofenac may be confused with Diflucan&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cataflam&reg; may be confused with Catapres&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Voltaren may be confused with traMADol, Ultram&reg;, Verelan&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Diclofenac may be confused with Duphalac brand name for lactulose [multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flexin: Brand name for diclofenac [Argentina], but also the brand name for cyclobenzaprine [Chile] and orphenadrine [Israel]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flexin [Argentina] may be confused with Floxin brand name for flunarizine [Thailand], norfloxacin [South Africa], ofloxacin [U.S., Canada], and perfloxacin [Philippines]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8016929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distension, abdominal pain, constipation, diarrhea, dyspepsia, flatulence, GI perforation, heartburn, nausea, peptic ulcer/GI bleed, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia, bleeding time increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver enzyme abnormalities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal function abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, alopecia, anaphylactoid reactions, anaphylaxis, angioedema, aplastic anemia, anxiety, appetite changes, arrhythmia, aseptic meningitis, asthma, azotemia, blurred vision, chest pain, CHF, colitis, coma, confusion, conjunctivitis, cystitis, depression, diplopia, disorientation, dreams abnormal, drowsiness, dyspnea, dysuria, ecchymosis, eosinophilia, eructation, erythema multiforme, esophageal lesions, esophagitis, exfoliative dermatitis, fever, fulminant hepatitis, gastritis, glossitis,hallucination, hearing impairment, hearing loss, hematemesis, hematuria, hemoglobin decreased, hemolytic anemia, hepatic failure, hepatic necrosis, hepatitis, hepatotoxicity, hyper-/hypotension, hyper-/hypoglycemia, infection, insomnia, interstitial nephritis, intestinal perforation, jaundice, laryngeal edema, leukopenia, lymphadenopathy, malaise, melena, memory disturbance, meningitis, MI, nephrotic syndrome, nervousness,  oliguria, palpitation, pancreatitis, pancytopenia, paresthesia, pharynx edema, photosensitivity, pneumonia, polyuria, proteinuria, psychotic reactions, purpura, rectal bleeding, renal failure, renal papillary necrosis, respiratory depression, seizure, sepsis, somnolence, Stevens-Johnson syndrome, stomatitis, stroke, swelling of lips and tongue, syncope, tachycardia, taste disorder, thrombocytopenia, toxic epidermal necrolysis, tremor, urticaria, vasculitis, vertigo, weight change, weakness, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Rectal suppository",
"     </b>",
"     (CAN; not available in U.S.):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Also refer to adverse reactions associated with oral formulations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening:  Local: Bleeding, hemorrhoid exacerbation, proctitis, rectal irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10885886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diclofenac or any component; history of asthma, urticaria, or allergic-type reaction to aspirin or other NSAIDs; patients with the \"aspirin triad\" [asthma, rhinitis (with or without nasal polyps), and aspirin intolerance] (fatal asthmatic and anaphylactoid reactions may occur in these patients); perioperative pain in the setting of coronary artery bypass graft (CABG)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10885925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and decrease the dose in patients with decreased hepatic function; closely monitor patients with abnormal LFTs; severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred. Use with caution in patients with asthma; asthmatic patients may have aspirin-sensitive asthma which may be associated with severe and potentially fatal bronchospasm when aspirin or NSAIDs are administered. Anemia (due to occult or gross blood loss from the GI tract, fluid retention, or other effect on erythropoiesis) may occur; monitor hemoglobin and hematocrit in patients receiving long-term therapy. Use with caution and monitor carefully in patients with coagulation disorders or those receiving anticoagulants; NSAIDs inhibit platelet aggregation and may prolong bleeding time. Oral solution contains phenylalanine (25 mg/packet); use with caution in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10885887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including potentially fatal MI and stroke",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease; carefully evaluate cardiovascular risk profile prior to prescribing; use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk. Use is contraindicated for treatment of perioperative pain in the setting of CABG surgery",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; an increased incidence of MI and stroke was found in patients receiving COX-2 selective NSAIDs for the treatment of pain within the first 10-14 days after CABG surgery. NSAIDs may cause fluid retention, edema, and new onset or worsening of pre-existing hypertension; use with caution in patients with hypertension, CHF, or fluid retention. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs; may interfere with aspirin&rsquo;s cardioprotective effect.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     NSAIDs may increase the risk of gastrointestinal inflammation, ulceration, bleeding, and perforation",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . These events, which can be potentially fatal, may occur at any time during therapy, and without warning. Avoid the use of NSAIDs in patients with active GI bleeding or ulcer disease. Use NSAIDs with extreme caution in patients with a history of GI bleeding or ulcers (these patients have a 10-fold increased risk for developing a GI bleed). Use NSAIDs with caution in patients with other risk factors which may increase GI bleeding (eg, concurrent therapy with aspirin, anticoagulants, and/or corticosteroids, longer duration of NSAID use, smoking, use of alcohol, and poor general health). Use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     NSAIDs may compromise existing renal function. Renal toxicity may occur in patients with impaired renal function, dehydration, heart failure, liver dysfunction, and those taking diuretics and ACE inhibitors; use with caution in these patients; monitor renal function closely. NSAIDs are not recommended for use in patients with advanced renal disease. Long-term use of NSAIDs may cause renal papillary necrosis and other renal injury.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fatal asthmatic and anaphylactoid reactions may occur in patients with the &ldquo;aspirin triad&rdquo; who receive NSAIDs. NSAIDs may cause serious dermatologic adverse reactions, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Avoid use of NSAIDs in late pregnancy as they may cause premature closure of the ductus arteriosus. Avoid the use of diclofenac in patients with hepatic porphyria (eg, variegate porphyria, acute intermittent porphyria, porphyria cutanea tarda); acute attacks of porphyria may occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Cases of drug-induced hepatotoxicity, including hepatic failure, resulting in death or requiring transplantation, have been reported. A potential for liver function test elevation exists with use of any diclofenac-containing product. Transaminase elevations generally occur within the first 2 months of therapy but may occur at any time; initiate monitoring after 4-8 weeks of therapy. Discontinue therapy immediately if abnormal liver tests persist or worsen, if clinical signs and/or symptoms consistent with liver disease develop, or if systemic manifestations occur (eg, eosinophilia, rash, abdominal pain, diarrhea, dark urine).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral solution is only indicated for acute treatment of migraine; not indicated for migraine prophylaxis or cluster headache. The oral solution is not bioequivalent to other forms of diclofenac (even if same dose); do not interchange products.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8016932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C9 (weak), CYP2E1 (weak), CYP3A4 (weak), UGT1A6",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8016933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May increase the serum concentration of Diclofenac (Systemic). Management: Consider using a lower dose of diclofenac when used together with a strong CYP2C9 inhibitor.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: UGT1A6 Inhibitors may increase the serum concentration of Deferiprone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Diclofenac (Systemic). Management: Consider using a lower dose of diclofenac when used together with voriconazole.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10885927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Delayed oral absorption has been reported with food for single doses but not with chronic multiple-dose administration.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8016838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (oral)/D (&ge;30 weeks gestation [oral]) (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8016839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, manufacturers classify most dosage forms of diclofenac as pregnancy category C (oral: Category D &ge;30 weeks gestation). Diclofenac crosses the placenta and can be detected in fetal tissue and amniotic fluid. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of a NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including: Myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). Product labeling for Zipsor&reg; specifically notes that use at &ge;30 weeks gestation should be avoided and, therefore, classifies diclofenac as pregnancy category D at this time. Use in the third trimester is contraindicated in the Canadian labeling. The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication. A registry is available for pregnant women exposed to autoimmune medications including diclofenac. For additional information contact the Organization of Teratology Information Specialists, OTIS Autoimmune Diseases Study, at 877-311-8972",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10886065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, liver enzymes (periodically during chronic therapy starting 4-8 weeks after initiation); monitor urine output, BUN, serum creatinine in patients receiving diuretics",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10885929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase, which results in decreased formation of prostaglandin precursors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10886045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic; undergoes first-pass metabolism; in the liver, undergoes hydroxylation then glucuronide and sulfate conjugation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: 2.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cambia&trade;: 0.25 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cataflam&reg;: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Voltaren&reg;: 2.22 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Voltaren&reg;-XR: 5.25 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: About 65% of the dose is eliminated in the urine and ~35% in the bile (primarily as conjugated forms); little or no unchanged drug is excreted in urine or bile",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10886066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/32/20998?source=see_link\">",
"      see \"Diclofenac (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; report any signs of blood in stool, GI bleeding, weight gain, edema, skin rash, yellow skin",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10886067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diclofenac potassium = Cataflam&reg;; potassium content: 5.8 mg (0.15 mEq) per 50 mg tablet",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brogden RN, Heel RC, Pakes GE, et al, &ldquo;Diclofenac Sodium: A Review of Its Pharmacological Properties and Therapeutic Use in Rheumatic Diseases and Pain of Varying Origin,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1980, 20(1):24-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/52/31560/abstract-text/6772422/pubmed\" id=\"6772422\" target=\"_blank\">",
"        6772422",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haapasaari J, Wuolijoki E, and Ylijoki H, &ldquo;Treatment of Juvenile Rheumatoid Arthritis With Diclofenac Sodium,&rdquo;",
"      <i>",
"       Scand J Rheumatol",
"      </i>",
"      , 1983, 12(4):325-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/52/31560/abstract-text/6361986/pubmed\" id=\"6361986\" target=\"_blank\">",
"        6361986",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hashkes PJ and Laxer RM, \"Medical Treatment of Juvenile Idiopathic Arthritis,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2005, 294(13):1671-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/52/31560/abstract-text/16204667/pubmed\" id=\"16204667\" target=\"_blank\">",
"        16204667",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15968 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C9BE2142DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_52_31560=[""].join("\n");
var outline_f30_52_31560=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016815\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016831\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016832\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10885590\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10886046\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017239\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016834\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016830\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10886047\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10885928\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10885885\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016829\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016929\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10885886\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10885925\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10885887\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016932\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016933\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10885927\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016838\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016839\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10886065\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10885929\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10886045\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10886066\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10886067\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15968\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15968|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/63/15348?source=related_link\">",
"      Diclofenac (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/51/10036?source=related_link\">",
"      Diclofenac (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/1/32787?source=related_link\">",
"      Diclofenac (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/43/8890?source=related_link\">",
"      Diclofenac (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/32/20998?source=related_link\">",
"      Diclofenac (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/21/24920?source=related_link\">",
"      Diclofenac (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/29/2518?source=related_link\">",
"      Diclofenac (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/43/1720?source=related_link\">",
"      Diclofenac (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_52_31561="Treatment of hyperprolactinemia due to lactotroph adenoma and other causes";
var content_f30_52_31561=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/52/31561/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/52/31561/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/52/31561/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/52/31561/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/52/31561/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/52/31561/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/52/31561/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactotroph adenomas (prolactinomas) are more amenable to pharmacologic treatment than any other kind of pituitary adenoma because of the availability of dopamine agonists, which usually decrease both the secretion and size of these tumors. For the minority of lactotroph adenomas that do not respond to dopamine agonists, other treatments must be used. Hyperprolactinemia due to other causes should also be treated if it causes hypogonadism.",
"   </p>",
"   <p>",
"    This topic will review the major issues concerning the therapy of hyperprolactinemia due to lactotroph adenomas and other causes, with the exception of therapy during pregnancy, which is discussed separately. The causes, clinical manifestations, and diagnosis of hyperprolactinemia are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/34/41510?source=see_link\">",
"     \"Management of lactotroph adenoma (prolactinoma) during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22167?source=see_link\">",
"     \"Causes of hyperprolactinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19254?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two principal reasons why patients with hyperprolactinemia may need to be treated: existing or impending neurologic symptoms due to the size of a lactotroph adenoma, and hypogonadism or other symptoms due to hyperprolactinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Our approach to management is similar to that suggested by the Endocrine Society Guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Adenoma size",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lactotroph adenoma 1 cm or more in size is a",
"    <strong>",
"     macroadenoma",
"    </strong>",
"    . Treatment is usually essential when the tumor is large enough to cause neurologic symptoms, such as visual impairment or headache. Treatment is usually desirable when the adenoma extends outside of the sella and abuts or elevates the optic chiasm, or invades the cavernous or sphenoid sinuses or the clivus; lesions of this size are likely to continue to grow and eventually cause neurologic symptoms.",
"   </p>",
"   <p>",
"    The tumor is a",
"    <strong>",
"     microadenoma",
"    </strong>",
"    when it is less than 1 cm in diameter. Studies of the natural history of microadenomas show that 95 percent do not enlarge during four to six years of observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The 5 percent that do enlarge should be treated because of the increase in size alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Symptoms of hyperprolactinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of hyperprolactinemia is usually desirable when it causes hypogonadism by suppressing gonadotropin secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19254?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In women, hypogonadism can cause infertility, oligomenorrhea or amenorrhea, and hypoestrogenemia, which can eventually lead to osteoporosis.",
"     </li>",
"     <li>",
"      In men, hypogonadism can cause decreased libido and energy, and eventually loss of sexual hair, osteoporosis, and loss of muscle mass. Hyperprolactinemia in men may also be associated with impotence, even when the serum testosterone concentration is normal. The mechanism is unknown, but the impotence usually improves dramatically when the hyperprolactinemia is corrected [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hyperprolactinemia can cause galactorrhea in women and very rarely may do so in men. For some patients, however, the galactorrhea is not sufficiently bothersome to require treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DOPAMINE AGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A dopamine agonist drug should usually be the first treatment for patients with hyperprolactinemia of any cause, including lactotroph adenomas of all sizes, because these drugs decrease hyperprolactinemia due to any cause and decrease the size and secretion of most lactotroph adenomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/6\">",
"     6",
"    </a>",
"    ]. Other approaches must be considered for the minority of patients whose adenomas are resistant to dopamine agonists or who cannot tolerate these drugs and for those who are taking a medication, such as an antipsychotic drug, that cannot be discontinued.",
"   </p>",
"   <p>",
"    Several dopamine agonists have been used in patients with hyperprolactinemia. Knowing their respective characteristics, what therapeutic effects to expect, and what side effects might occur and how to avoid them will increase the chance of a successful result.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       Cabergoline",
"      </a>",
"      &mdash; Cabergoline is an ergot dopamine agonist that is administered once or twice a week and has much less tendency to cause nausea than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. It may be effective in patients resistant to bromocriptine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/9\">",
"       9",
"      </a>",
"      ]. At the high doses used for the treatment of Parkinson disease, cabergoline is associated with an increased risk of valvular heart disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/10,11\">",
"       10,11",
"      </a>",
"      ], but at the lower doses generally used for the treatment of hyperprolactinemia, cabergoline is not clearly associated with this risk. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Valvular heart disease'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/63/32762?source=see_link&amp;anchor=H19#H19\">",
"       \"Pharmacologic treatment of Parkinson disease\", section on 'Valvular heart disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"       Bromocriptine",
"      </a>",
"      &mdash; Bromocriptine is an ergot derivative that has been used for approximately three decades for treatment of hyperprolactinemia. It should be given twice a day to have optimal therapeutic effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pergolide &mdash; Pergolide is also an ergot derivative and had been used primarily for the treatment of Parkinson disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/12\">",
"       12",
"      </a>",
"      ]. However, when used for hyperprolactinemia, typical doses range from 0.05 to 1.0",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      At the high dose used for Parkinson disease (&gt;3",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      pergolide is associated with an increased risk of valvular heart disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. In the United States, pergolide was voluntarily withdrawn from the market in March 2007 due to this risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/63/32762?source=see_link&amp;anchor=H19#H19\">",
"       \"Pharmacologic treatment of Parkinson disease\", section on 'Valvular heart disease'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H8\">",
"       'Valvular heart disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Other &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/23/42355?source=see_link\">",
"       Quinagolide",
"      </a>",
"      (CV 205-502), a nonergot dopamine agonist that is given once a day, is available in some countries but not the United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/14-16\">",
"       14-16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Therapeutic efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dopamine agonists decrease prolactin secretion (",
"    <a class=\"graphic graphic_figure graphicRef72539 \" href=\"mobipreview.htm?28/2/28717\">",
"     figure 1",
"    </a>",
"    ) and reduce the size of the lactotroph adenoma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86088 \" href=\"mobipreview.htm?15/24/15746\">",
"     image 1",
"    </a>",
"    ) in more than 90 percent of patients. Both effects are mediated by binding of the drug to cell-surface dopamine receptors, leading to reductions in the synthesis and secretion of prolactin and in adenoma cell size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/17\">",
"     17",
"    </a>",
"    ]. A review of 13 studies, as an example, showed that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    reduced the serum prolactin concentration to normal in 229 of 280 women (82 percent) with hyperprolactinemia and, in 12 studies, in 66 of 92 patients (71 percent) with lactotroph macroadenomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     Cabergoline",
"    </a>",
"    may be superior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    in decreasing the serum prolactin concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. This was illustrated in a trial of 459 women with hyperprolactinemia and amenorrhea who had microadenomas or no obvious cause; the patients who were randomized to cabergoline were more likely to have a reduction of serum prolactin to normal (83 versus 52 percent in the bromocriptine group) (",
"    <a class=\"graphic graphic_figure graphicRef72539 \" href=\"mobipreview.htm?28/2/28717\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/7\">",
"     7",
"    </a>",
"    ]. In a retrospective study of 455 patients treated with cabergoline, serum prolactin concentrations normalized in 86 percent, including 41 of the 58 patients (70 percent) who were resistant to bromocriptine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/9\">",
"     9",
"    </a>",
"    ]. Visual field abnormalities resolved in 70 percent of patients with pre-treatment defects, and pituitary tumor size decreased in 123 of the 190 patients who had pituitary adenomas. The median initial dose of cabergoline was 1 mg weekly, and it was later reduced to 0.5 mg weekly in 25 percent of patients with no increase in serum prolactin concentrations.",
"   </p>",
"   <p>",
"    One report described that increasing the dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    sufficiently lowered the serum prolactin to normal in all but one of 150 men and women with lactotroph adenomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/18\">",
"     18",
"    </a>",
"    ]. In the 26 who had previously been classified as resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    , the mean weekly dose of cabergoline required was 5.2",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    0.6 mg and was as high as 12 mg.",
"   </p>",
"   <p>",
"    The effect on adenoma size is most apparent in patients with lactotroph macroadenomas (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86088 \" href=\"mobipreview.htm?15/24/15746\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/23/42355?source=see_link\">",
"     Quinagolide",
"    </a>",
"    appears to have equivalent therapeutic effects in reducing serum prolactin and adenoma size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/15,20\">",
"     15,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fall in serum prolactin typically occurs within the first two to three weeks of therapy with a dopamine agonist (",
"    <a class=\"graphic graphic_figure graphicRef72539 \" href=\"mobipreview.htm?28/2/28717\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/7\">",
"     7",
"    </a>",
"    ]; in patients with macroadenomas it always precedes any decrease in adenoma size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/15\">",
"     15",
"    </a>",
"    ]. The decrease in adenoma size can, in many patients, be detected by imaging within six weeks after initiation of treatment; in some patients, however, a decrease is not apparent for six months (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86088 \" href=\"mobipreview.htm?15/24/15746\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/19\">",
"     19",
"    </a>",
"    ]. These benefits occur even in patients who have impaired visual fields before therapy, occurring in 9 of 10 such patients in each of two reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Overall, the greater the decrease in serum prolactin concentration, the greater the decrease in adenoma size, although there is considerable variation from patient to patient.",
"   </p>",
"   <p>",
"    Following the decrease in serum prolactin and adenoma size in patients with macroadenomas, visual and pituitary function often return to normal. Vision usually begins to improve within days after the initiation of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. There is recovery of menses and fertility in women and of testosterone secretion, sperm count, and erectile function in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/6,7,23-25\">",
"     6,7,23-25",
"    </a>",
"    ]. Patients with macroadenomas who are hypothyroid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoadrenal may also have a return of these functions to normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The therapeutic efficacy of dopamine agonists may be blunted by the concurrent use of drugs known to raise serum prolactin concentrations, including neuroleptic drugs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , sulpiride,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/43/1717?source=see_link\">",
"     domperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/35/16950?source=see_link\">",
"     reserpine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal side effects of dopamine agonist drugs are nausea, postural hypotension, and mental fogginess. Less common side effects include nasal stuffiness, depression, Raynaud phenomenon, alcohol intolerance, and constipation.",
"   </p>",
"   <p>",
"    Side effects are more likely to occur when treatment is initiated or the dose is increased. They can be avoided in most patients by starting with a small dose (one-half of the lowest strength pill of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    ) once a day or half a pill of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    twice a week and by giving it with food or at bedtime. A small percentage of patients have side effects even at the lowest doses. In women, nausea can be avoided by intravaginal administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/27\">",
"     27",
"    </a>",
"    ]. Nausea appears to be less when cabergoline is used.",
"   </p>",
"   <p>",
"    CSF rhinorrhea may occur during dopamine agonist treatment for very large lactotroph adenomas that extend inferiorly and invade the floor of the sella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Although uncommon, early recognition and neurosurgical evaluation of this complication is important because of the potential risk of bacterial meningitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Valvular heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     Cabergoline",
"    </a>",
"    and pergolide are associated with valvular heart disease in patients with Parkinson disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In the United States, pergolide was voluntarily withdrawn from the market in March 2007 due to this risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/13\">",
"     13",
"    </a>",
"    ]. The association appears to be dose-dependent, and the doses used for Parkinson disease (&gt;3",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    are typically much higher than those used for hyperprolactinemia (0.5 to 1.5",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/63/32762?source=see_link&amp;anchor=H19#H19\">",
"     \"Pharmacologic treatment of Parkinson disease\", section on 'Valvular heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following the reports of the association of cardiac valvulopathy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    use in patients with Parkinson disease, a number of studies reported cardiac ultrasonography findings in patients taking cabergoline for hyperprolactinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/30-38\">",
"     30-38",
"    </a>",
"    ]. In one report of 50 patients with lactotroph adenoma treated with cabergoline, moderate tricuspid regurgitation was more frequent (54 percent) than in 50 age- and gender-matched subjects (18 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/32\">",
"     32",
"    </a>",
"    ]. However, in a review of nine studies published through 2008, the majority did not demonstrate an increased risk of valvular regurgitation with cabergoline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/30\">",
"     30",
"    </a>",
"    ]. Most patients were using standard doses of cabergoline for hyperprolactinemia (0.5 to 1.5",
"    <span class=\"nowrap\">",
"     mg/week).",
"    </span>",
"    Therefore, the possible risk of valvular disease with the higher cabergoline doses and longer durations of treatment sometimes needed to control lactotroph adenomas remains unknown.",
"   </p>",
"   <p>",
"    Based upon the available data, we suggest using the lowest dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    necessary to lower prolactin to normal. We suggest a trial of withdrawal if the prolactin concentration and the size of the pituitary have been normal for two or more years (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Withdrawal of therapy'",
"    </a>",
"    below). We also suggest ordering cardiac ultrasonography approximately every two years in patients who take larger than typical doses of cabergoline (eg, greater than 2 mg per week).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Microadenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the high rate of efficacy and low rate of side effects with dopamine agonists, as well as the consequences of hypogonadism, we recommend that these agents be used in patients with lactotroph microadenomas who have any degree of hypogonadism.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       Cabergoline",
"      </a>",
"      is the best initial choice in most circumstances because it is most likely to be effective and least likely to cause side effects. Our approach is consistent with the 2011 Endocrine Society hyperprolactinemia clinical guidelines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/2\">",
"       2",
"      </a>",
"      ]. The initial dose should be 0.25 mg twice a week or 0.5 mg once a week.",
"     </li>",
"     <li>",
"      For a woman who wishes to become pregnant,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      might be a better first choice because there is more evidence that bromocriptine does not cause birth defects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/39\">",
"       39",
"      </a>",
"      ]. However, data to date suggest that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      is also safe in early pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/34/41510?source=see_link\">",
"       \"Management of lactotroph adenoma (prolactinoma) during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"       Bromocriptine",
"      </a>",
"      should be started at a dose of 1.25 mg after dinner or at bedtime for one week, then increased to 1.25 mg twice a day (after breakfast and after dinner or at bedtime).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;After one month of therapy, the patient should be evaluated for side effects and serum prolactin should be measured. Subsequent treatment depends upon the response:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the serum prolactin concentration is normal and no side effects have occurred, the initial dose should be continued. In this setting, gonadal function will probably return within a few months.",
"     </li>",
"     <li>",
"      If the serum prolactin concentration has not decreased to normal but no side effects have occurred, the dose should be increased gradually to as much as 1.5 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      two or three times a week or 5 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      twice a day. Whatever dose results in a normal serum prolactin value should be continued.",
"     </li>",
"     <li>",
"      If the serum prolactin concentration does not decrease sufficiently to restore normal gonadal function in response to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      and if compliance seems good, changing to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      may be effective.",
"     </li>",
"     <li>",
"      If the patient cannot tolerate the first dopamine agonist administered, another can be tried. In women, nausea can be avoided by vaginal administration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If none of these approaches are effective, transsphenoidal surgery or ovulation induction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate or gonadotropins can be considered if a woman wishes to become pregnant. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Transsphenoidal surgery'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/10/13482?source=see_link\">",
"     \"Overview of ovulation induction\"",
"    </a>",
"    .) If, on the other hand, the woman does not want to become pregnant in the near future, estrogen and progesterone replacement can be considered (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Estrogen'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    If the patient tolerates the dopamine agonist and the serum prolactin eventually returns to normal, the drug should be continued unless the patient becomes pregnant. After approximately one year, the dose can often be decreased. If the prolactin has been normal for two or more years and no adenoma is seen on MRI, discontinuation of the drug can be considered (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Withdrawal of therapy'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    After menopause, the drug can be discontinued and the serum prolactin concentration can be allowed to rise. Imaging should be performed if the value rises above 200",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (200",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    SI units) to determine if the adenoma has increased to a clinically important size. If so, drug therapy should be resumed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Macroadenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients with lactotroph macroadenomas, no matter how large or how severe the neurologic sequelae, should also be initiated with a dopamine agonist, starting with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/2\">",
"     2",
"    </a>",
"    ], as described above for patients with microadenomas (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Microadenomas'",
"    </a>",
"    above). The dose should be increased once a month, if necessary, until the serum prolactin concentration becomes normal. If vision was abnormal before therapy, it should be reassessed within one month, although improvement may occur within a few days. An MRI should be repeated in 6 to 12 months to determine if the size of the adenoma has decreased.",
"   </p>",
"   <p>",
"    In most patients with lactotroph macroadenomas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The size of the adenoma decreases to approximately the same degree as the serum prolactin concentration, although the relationship varies from patient to patient.",
"     </li>",
"     <li>",
"      The decrease in size usually cannot be demonstrated until weeks or months after the prolactin secretion has decreased (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef86088 \" href=\"mobipreview.htm?15/24/15746\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The size of the adenoma can continue to decrease for years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the serum prolactin concentration has been normal for at least one year and the adenoma has decreased markedly in size, the dose of the dopamine agonist can be decreased gradually, as long as the serum prolactin remains normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/43\">",
"     43",
"    </a>",
"    ]. Discontinuation can be considered in those patients who had macroadenomas of modest size, eg, 1.0 to 1.5 cm, whose serum prolactin concentrations have been normal for more than two years, and whose adenomas can no longer be visualized by MRI.",
"   </p>",
"   <p>",
"    If the drug is discontinued, the prolactin concentration and the size of the adenoma by MRI must be monitored. Discontinuation should probably not be considered if the adenoma was initially &gt;2 cm, or if it can still be visualized by MRI during treatment, or if the prolactin has not become normal during treatment. The agonist should not be discontinued entirely, even after menopause, because hyperprolactinemia will probably recur and the adenoma may increase in size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Withdrawal of therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We recommend the following approach in patients who do not have a complete response:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient cannot tolerate the first agonist tried or the adenoma does not respond to it, another agonist should be tried.",
"     </li>",
"     <li>",
"      If the patient cannot tolerate or the adenoma does not respond to agonist therapy, transsphenoidal surgery should be performed, and, if a significant amount of adenoma tissue remains after surgery, radiation therapy should be administered. Surgery can also be considered for the woman who has a giant adenoma and is contemplating pregnancy (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Transsphenoidal surgery'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Withdrawal of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several papers have reported the consequences of discontinuation of dopamine agonist treatment in patients who have hyperprolactinemia. Recurrence of hyperprolactinemia and increase in adenoma size has been variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/44,47-51\">",
"     44,47-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one prospective study of 200",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    -treated patients with hyperprolactinemia (25 with idiopathic hyperprolactinemia, 105 with microadenomas, and 70 with macroadenomas), therapy was withdrawn when serum prolactin concentrations were normal and MRI showed no adenoma (or &gt;50 percent reduction with no cavernous sinus invasion and &gt;5 mm distance from the optic chiasm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/44\">",
"     44",
"    </a>",
"    ]. After two to five years of observation the following results were seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperprolactinemia recurred in 24, 31, and 36 percent of patients with idiopathic hyperprolactinemia, microadenomas, and macroadenomas, respectively.",
"     </li>",
"     <li>",
"      Adenoma regrowth was not seen in any patient.",
"     </li>",
"     <li>",
"      Hyperprolactinemia in patients with adenomas was more likely to recur if an adenoma remnant was seen on MRI than if it was not when treatment was stopped (78 versus 33 percent for macroadenomas, and 42 versus 26 percent for microadenomas).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients with remnant macroadenoma had tumor recurrence by seven years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/52\">",
"     52",
"    </a>",
"    ]. However, giant adenomas (&gt;3 cm) may behave more aggressively, as shown by case reports of rapid, substantial regrowth within weeks of discontinuation of dopamine agonist medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, a number of other studies report higher rates of recurrent hyperprolactinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/46,47,50\">",
"     46,47,50",
"    </a>",
"    ]. In a meta-analysis of 19 studies with a total of 743 patients, the overall rate of remission (persistent normoprolactinemia) after withdrawal of dopamine agonist therapy was 21 percent (32, 21, and 16 percent for idiopathic hyperprolactinemia, microprolactinomas, and macroprolactinomas, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/51\">",
"     51",
"    </a>",
"    ]. Other findings included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher rate of remission in studies in which",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      was used (35 percent in four studies) than in those in which",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      was used (20 percent in 12 studies).",
"     </li>",
"     <li>",
"      Higher rates of remission in studies with treatment duration longer than 24 months (34 percent) compared with studies with shorter treatment duration (16 percent).",
"     </li>",
"     <li>",
"      Higher remission rate (55 percent) in studies where a 50 percent tumor reduction was achieved in all patients before stopping therapy; a 55 percent remission rate was seen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, hyperprolactinemia may recur in a considerable number of patients after stopping dopamine agonist therapy. The probability of remission is best the longer the serum prolactin has been normal and no adenoma has been seen by MRI, preferably for at least two years.",
"   </p>",
"   <p>",
"    In a patient whose serum prolactin decreases to low-normal in response to dopamine agonist treatment, we suggest attempting to decrease the dose gradually, as long as the prolactin remains within the normal range. If a patient has a normal prolactin and no evidence of the adenoma by MRI for two years while taking a low dose, eg, 0.25 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    for two years, we suggest a trial of discontinuation of the drug. This approach is consistent with that of the Endocrine Society 2011 clinical guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend not stopping the dopamine agonist if the prolactin increases above normal while gradually decreasing the drug. If the drug is discontinued, prolactin should be measured after three months and yearly thereafter. If the prolactin increases substantially, eg, to &gt;100",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    especially in a patient who originally had a macroadenoma, an MRI should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TRANSSPHENOIDAL SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transsphenoidal surgery should be considered when:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dopamine agonist treatment has been unsuccessful in lowering the serum prolactin concentration or size of the adenoma and symptoms or signs due to hyperprolactinemia or adenoma size persist during treatment.",
"     </li>",
"     <li>",
"      A woman has a giant lactotroph adenoma, eg, &gt;3 cm, and wishes to become pregnant even if the adenoma responds to a dopamine agonist. The rationale for this approach is that if the patient becomes pregnant and discontinues the agonist for the duration of pregnancy, the adenoma may increase to a clinically important size before delivery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgery is usually successful in substantially reducing serum prolactin concentrations in patients with lactotroph adenomas, sometimes to normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. It is a safer procedure when performed by an experienced surgeon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/57\">",
"     57",
"    </a>",
"    ]. Surgery, however, has the following limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Not all of the adenoma tissue is excised in many patients, particularly those with macroadenomas. In one report of transsphenoidal surgery in 100 patients with lactotroph adenomas, 88 percent with preoperative serum prolactin concentrations &lt;100",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (100",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      SI units) had normal values after surgery, as compared with only 50 percent of those with preoperative concentrations &gt;100",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/54\">",
"       54",
"      </a>",
"      ]. Only two of nine men with invasive macroadenomas had near-normal serum prolactin concentrations after surgery.",
"     </li>",
"     <li>",
"      The adenoma and hyperprolactinemia may recur within several years after surgery. Two studies evaluated 55 patients with normal serum prolactin concentrations shortly after transsphenoidal surgery for lactotroph microadenomas. Recurrent hyperprolactinemia occurred in 50 and 39 percent of patients at four and five years after surgery, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/55,56\">",
"       55,56",
"      </a>",
"      ]. In a series of 409 women, the best single predictor of persistent cure was a serum prolactin concentration of &le;5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (5",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      SI units) on the first postoperative day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Side effects are the same as may occur during and after transsphenoidal surgery for any kind of pituitary adenoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supervoltage radiation decreases the size and secretion of lactotroph adenomas, but the fall in prolactin secretion occurs so slowly that the serum concentration may still be elevated many years after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. One study, as an example, evaluated 34 patients with lactotroph or lactotroph-somatotroph adenomas who were treated by supervoltage radiation; a few had normalization of serum prolactin as late as 10 years after therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consequently, radiation is primarily used to prevent regrowth of residual tumor in a patient with a very large macroadenoma after transsphenoidal debulking. It should not be used for the primary treatment of patients with macroadenomas or at all for those with microadenomas.",
"   </p>",
"   <p>",
"    Complications of radiation include transient nausea, lassitude, and loss of taste and smell, loss of scalp hair at the radiation portals during and shortly after the treatment, and possible damage to the optic nerve and neurologic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/1\">",
"     1",
"    </a>",
"    ]. There is also a 50 percent chance of loss of anterior pituitary hormone secretion during the subsequent 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ESTROGEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen, along with a progestin, can be considered as sole therapy in women who have lactotroph microadenomas causing hyperprolactinemia and hypogonadism but who cannot tolerate or do not respond to dopamine agonists and do not want to become pregnant. Estrogen is also a reasonable option for women with hyperprolactinemia and amenorrhea due to antipsychotic agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19254?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"    </a>",
"    .) Since estrogen treatment might pose a slight risk of increasing the size of the adenoma, the serum prolactin concentration should be measured periodically in these patients. Estrogen should",
"    <strong>",
"     not",
"    </strong>",
"    be used as the sole treatment for lactotroph macroadenomas.",
"   </p>",
"   <p>",
"    Estrogen and progestin can be administered separately in low doses as they would be for the treatment of hypogonadism of any etiology, or estrogen can be administered in the form of an oral contraceptive. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link\">",
"     \"Overview of the use of estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT OF NON-ADENOMA CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of hyperprolactinemia due to an abnormality other than a lactotroph adenoma varies depending on the cause:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hypothalamic and pituitary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;If removal of the adenoma or mass is not possible, the hyperprolactinemia should be treated with a dopamine agonist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Antipsychotic drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an antipsychotic drug is causing hyperprolactinemia and hypogonadism but cannot be discontinued because it is essential, several possible treatment options can be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Addition of a dopamine agonist. This option should be undertaken very cautiously, since it might counteract the dopamine antagonist property of the antipsychotic drug.",
"     </li>",
"     <li>",
"      Change to an antipsychotic drug that does not raise prolactin, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      (Seroquel). This course should only be considered in conjunction with the treating psychopharmacologist.",
"     </li>",
"     <li>",
"      Addition of the antipsychotic drug",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      to the existing antipsychotic drug. This drug has both dopamine agonist and antagonist properties and dampens hyperprolactinemia when added to other antipsychotic drugs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       Risperidone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31561/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Addition of an estrogen and progestin to treat the estrogen deficiency and prevent bone loss in women. This approach will not treat the hyperprolactinemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;If hyperprolactinemia is solely the result of hypothyroidism, it will remit as the hypothyroidism is corrected, so no other treatment is necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/6/25698?source=see_link\">",
"       \"Patient information: Prolactinoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/0/25603?source=see_link\">",
"       \"Patient information: High prolactin levels and prolactinomas (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the treatments now available, we make the following recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with lactotroph microadenomas and any degree of hypogonadism, we recommend initial treatment with a dopamine agonist (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Microadenomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      as the initial choice of dopamine agonists in most circumstances because it is most likely to be effective and least likely to cause side effects (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Dopamine agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of a possible association between high dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      use for Parkinson disease and valvular heart disease, we suggest using the lowest dose of cabergoline necessary to lower prolactin to normal (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Valvular heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who require higher than usual doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      (eg, greater than 2 mg per week), we suggest ordering cardiac ultrasonography every two years (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Valvular heart disease'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      For patients whose serum prolactin decreases to low-normal in response to dopamine agonist treatment, we suggest decreasing the dose gradually, as long as the prolactin remains within the normal range (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who have a normal serum prolactin and no evidence of adenoma on MRI while taking a low dose of dopamine agonist for at least two years, we suggest a trial of stopping the drug (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If the drug is discontinued, prolactin should be measured after three months and yearly thereafter. If the prolactin increases substantially, eg, to &gt;100",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      especially in a patient who originally had a macroadenoma, an MRI should be performed.",
"     </li>",
"     <li>",
"      If the patient cannot tolerate the first dopamine agonist administered, or serum prolactin concentrations do not normalize, we suggest switching to a second dopamine agonist (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Dopamine agonists'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Starting doses and upward titration of dose based upon clinical response are reviewed above (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Microadenomas'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      In women with lactotroph microadenomas seeking fertility whose serum prolactin concentrations do not normalize with dopamine agonist therapy (and therefore do not ovulate), we suggest ovulation induction with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      citrate or gonadotropin therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/10/13482?source=see_link\">",
"       \"Overview of ovulation induction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with lactotroph macroadenomas, no matter how large or how severe the neurologic sequelae, we recommend initial treatment with a dopamine agonist (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Dosing is the same as that for microadenomas (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Microadenomas'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      We suggest transsphenoidal surgery when dopamine agonist treatment has been unsuccessful in lowering the serum prolactin concentration or size of the macroadenoma and symptoms or signs due to hyperprolactinemia or adenoma size persist during treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Transsphenoidal surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We also suggest transsphenoidal surgery in women with giant lactotroph adenomas (&gt;3 cm) who wish to become pregnant, even if the adenoma responds to a dopamine agonist (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The rationale for this approach is that if such a patient becomes pregnant and discontinues the agonist for the duration of pregnancy, the adenoma may increase to a clinically important size before delivery (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Transsphenoidal surgery'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      In patients with large macroadenomas who have undergone transsphenoidal debulking and in whom considerable residual adenoma remains in a location not readily accessible to surgery, we suggest radiation therapy to prevent regrowth of residual adenoma (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We recommend not using radiation therapy for the primary treatment of patients with macroadenomas or at all for those with microadenomas (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In premenopausal women who have lactotroph microadenomas causing hyperprolactinemia and hypogonadism but who cannot tolerate or do not respond to dopamine agonists and do not want to become pregnant, we suggest estrogen and progestin replacement to prevent bone loss (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Estrogen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We also suggest gonadal steroid replacement therapy in patients with hyperprolactinemia and hypogonadism due to antipsychotic agents (estradiol-progestin in women and testosterone in men) if a satisfactory antipsychotic regimen that does not cause hyperprolactinemia cannot be found (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Antipsychotic drug use'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/1\">",
"      Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006; 65:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/2\">",
"      Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/3\">",
"      Schlechte J, Dolan K, Sherman B, et al. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989; 68:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/4\">",
"      Sisam DA, Sheehan JP, Sheeler LR. The natural history of untreated microprolactinomas. Fertil Steril 1987; 48:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/5\">",
"      Carter JN, Tyson JE, Tolis G, et al. Prolactin-screening tumors and hypogonadism in 22 men. N Engl J Med 1978; 299:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/6\">",
"      Vance ML, Evans WS, Thorner MO. Drugs five years later. Bromocriptine. Ann Intern Med 1984; 100:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/7\">",
"      Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994; 331:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/8\">",
"      Biller BM, Molitch ME, Vance ML, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996; 81:2338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/9\">",
"      Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999; 84:2518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/10\">",
"      Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/11\">",
"      Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/12\">",
"      Kleinberg DL, Boyd AE 3rd, Wardlaw S, et al. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl J Med 1983; 309:704.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA announces voluntary withdrawal of pergolide products (March 29, 2007). file://www.fda.gov/newsevents/newsroom/pressannouncements/2007/ucm108877.htm (Accessed on August 01, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/14\">",
"      Vance ML, Lipper M, Klibanski A, et al. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502. Ann Intern Med 1990; 112:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/15\">",
"      Di Sarno A, Landi ML, Marzullo P, et al. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 2000; 53:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/16\">",
"      Schultz PN, Ginsberg L, McCutcheon IE, et al. Quinagolide in the management of prolactinoma. Pituitary 2000; 3:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/17\">",
"      Tindall GT, Kovacs K, Horvath E, Thorner MO. Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 1982; 55:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/18\">",
"      Ono M, Miki N, Kawamata T, et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 2008; 93:4721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/19\">",
"      Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 1985; 60:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/20\">",
"      van der Lely AJ, Brownell J, Lamberts SW. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J Clin Endocrinol Metab 1991; 72:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/21\">",
"      Moster ML, Savino PJ, Schatz NJ, et al. Visual function in prolactinoma patients treated with bromocriptine. Ophthalmology 1985; 92:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/22\">",
"      Colao A, Di Sarno A, Landi ML, et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 1997; 82:3574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/23\">",
"      De Rosa M, Colao A, Di Sarno A, et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 1998; 138:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/24\">",
"      De Rosa M, Zarrilli S, Vitale G, et al. Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 2004; 89:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/25\">",
"      Colao A, Vitale G, Cappabianca P, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 2004; 89:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/26\">",
"      Warfield A, Finkel DM, Schatz NJ, et al. Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function. Ann Intern Med 1984; 101:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/27\">",
"      Kletzky OA, Vermesh M. Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia. Fertil Steril 1989; 51:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/28\">",
"      Leong KS, Foy PM, Swift AC, et al. CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas. Clin Endocrinol (Oxf) 2000; 52:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/29\">",
"      Davis JR, Sheppard MC, Heath DA. Giant invasive prolactinoma: a case report and review of nine further cases. Q J Med 1990; 74:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/30\">",
"      Valassi E, Klibanski A, Biller BM. Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 2010; 95:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/31\">",
"      Kars M, Delgado V, Holman ER, et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 2008; 93:3348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/32\">",
"      Colao A, Galderisi M, Di Sarno A, et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 2008; 93:3777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/33\">",
"      Wakil A, Rigby AS, Clark AL, et al. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 2008; 159:R11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/34\">",
"      Vallette S, Serri K, Rivera J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2009; 12:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/35\">",
"      Herring N, Szmigielski C, Becher H, et al. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 2009; 70:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/36\">",
"      Devin JK, Lakhani VT, Byrd BF 3rd, Blevins LS Jr. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract 2008; 14:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/37\">",
"      Lafeber M, Stades AM, Valk GD, et al. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinol 2010; 162:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/38\">",
"      Tan T, Cabrita IZ, Hensman D, et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol (Oxf) 2010; 73:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/39\">",
"      Turkalj I, Braun P, Krupp P. Surveillance of bromocriptine in pregnancy. JAMA 1982; 247:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/40\">",
"      Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996; 10:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/41\">",
"      Ricci E, Parazzini F, Motta T, et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002; 16:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/42\">",
"      Motta T, de Vincentiis S, Marchini M, et al. Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics. Fertil Steril 1996; 65:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/43\">",
"      Liuzzi A, Dallabonzana D, Oppizzi G, et al. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 1985; 313:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/44\">",
"      Colao A, Di Sarno A, Cappabianca P, et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003; 349:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/45\">",
"      Thorner MO, Perryman RL, Rogol AD, et al. Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J Clin Endocrinol Metab 1981; 53:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/46\">",
"      Van't Verlaat, JW, Croughs, RJ. Withdrawal of bromocriptine after long&ndash;term therapy for macroprolactinomas: Effect on plasma prolactin and tumor size. Clin Endocrinol 1991; 34:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/47\">",
"      Passos VQ, Souza JJ, Musolino NR, Bronstein MD. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 2002; 87:3578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/48\">",
"      Biswas M, Smith J, Jadon D, et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) 2005; 63:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/49\">",
"      Colao A, Di Sarno A, Guerra E, et al. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf) 2007; 67:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/50\">",
"      Kharlip J, Salvatori R, Yenokyan G, Wand GS. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 2009; 94:2428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/51\">",
"      Dekkers OM, Lagro J, Burman P, et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/52\">",
"      Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006; 27:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/53\">",
"      Feigenbaum SL, Downey DE, Wilson CB, Jaffe RB. Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up. J Clin Endocrinol Metab 1996; 81:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/54\">",
"      Randall RV, Laws ER Jr, Abboud CF, et al. Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas. Results in 100 patients. Mayo Clin Proc 1983; 58:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/55\">",
"      Serri O, Rasio E, Beauregard H, et al. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med 1983; 309:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/56\">",
"      Schlechte JA, Sherman BM, Chapler FK, VanGilder J. Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors. J Clin Endocrinol Metab 1986; 62:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/57\">",
"      Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997; 40:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/58\">",
"      Littley MD, Shalet SM, Reid H, et al. The effect of external pituitary irradiation on elevated serum prolactin levels in patients with pituitary macroadenomas. Q J Med 1991; 81:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/59\">",
"      Tsagarakis S, Grossman A, Plowman PN, et al. Megavoltage pituitary irradiation in the management of prolactinomas: long-term follow-up. Clin Endocrinol (Oxf) 1991; 34:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/60\">",
"      Snyder PJ, Fowble BF, Schatz NJ, et al. Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med 1986; 81:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31561/abstract/61\">",
"      Byerly MJ, Marcus RN, Tran QV, et al. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res 2009; 107:218.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6630 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-190.81.197.98-68DAC4FE3C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_52_31561=[""].join("\n");
var outline_f30_52_31561=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Adenoma size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Symptoms of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DOPAMINE AGONISTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Therapeutic efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Valvular heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Microadenomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Macroadenomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Withdrawal of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TRANSSPHENOIDAL SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ESTROGEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT OF NON-ADENOMA CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hypothalamic and pituitary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Antipsychotic drug use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/6630\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6630|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/24/15746\" title=\"diagnostic image 1\">",
"      Lactotroph macroadenoma shrinkage dopamine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6630|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/2/28717\" title=\"figure 1\">",
"      Dopamine agonists in prolactinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22167?source=related_link\">",
"      Causes of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19254?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/34/41510?source=related_link\">",
"      Management of lactotroph adenoma (prolactinoma) during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/10/13482?source=related_link\">",
"      Overview of ovulation induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/0/25603?source=related_link\">",
"      Patient information: High prolactin levels and prolactinomas (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/6/25698?source=related_link\">",
"      Patient information: Prolactinoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/63/32762?source=related_link\">",
"      Pharmacologic treatment of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_52_31562="Risk factors for prostate cancer";
var content_f30_52_31562=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risk factors for prostate cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/52/31562/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/52/31562/contributors\">",
"     A Oliver Sartor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/52/31562/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/52/31562/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/52/31562/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/52/31562/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/52/31562/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/52/31562/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/52/31562/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate cancer is the second most common cancer in men worldwide, with an estimated 900,000 cases and 258,000 deaths in 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/1\">",
"     1",
"    </a>",
"    ]. The current lifetime risk of prostate cancer for men living in the United States is estimated to be approximately one in six [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rates of prostate cancer differ over 50-fold among various international populations (",
"    <a class=\"graphic graphic_figure graphicRef50243 \" href=\"mobipreview.htm?33/62/34798\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/3\">",
"     3",
"    </a>",
"    ]. However, interpretation of these data is complicated by dramatic changes in the incidence of prostate cancer in the US and other Western countries that have taken place over the past several decades. These changes have been primarily driven by the increased frequency of prostate biopsies performed in asymptomatic men because of an elevated prostate specific antigen (PSA) level. In the US, the incidence of prostate cancer dramatically rose in the early 1990s concomitant with the increasing utilization of PSA testing. After an initial peak, incidence rates fell, but they have persisted at a rate nearly twice that recorded in the pre-PSA era. A central argument against routine PSA screening is that many of these cancers, if left undetected, would never have become clinically meaningful during a man's lifetime. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=see_link\">",
"     \"Screening for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ascertainment biases constitute an important, but incomplete, explanation for the observed international variations in prostate cancer incidence. Countries that do not utilize PSA testing typically have a much lower rate of prostate cancer compared to those that do. Unless studies control for the number of prostate biopsies performed, it is difficult if not impossible to be definitive in the conclusions.",
"   </p>",
"   <p>",
"    Of the several known prostate cancer risk factors, the most important are age, ethnicity, genetic factors, and possibly dietary factors. The known risk factors for prostate cancer are reviewed here. Screening for prostate cancer and the clinical manifestations and diagnosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=see_link\">",
"     \"Screening for prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36101?source=see_link\">",
"     \"Clinical presentation and diagnosis of prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This review will focus on the most common histologic type of prostate malignancy (adenocarcinoma) which comprises over 99 percent of the malignancies which affect this organ. Other histologies include small cell neuroendocrine tumors, sarcomas, and lymphomas, which are rarely encountered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/52/24394?source=see_link\">",
"     \"Interpretation of prostate biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate cancer has one of the strongest relationships between age and any human malignancy (",
"    <a class=\"graphic graphic_figure graphicRef55572 \" href=\"mobipreview.htm?38/47/39679\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Clinically diagnosed prostate cancer rarely occurs before the age of 40, but the incidence rises rapidly thereafter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In data from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) program, the annual incidence of new cases of prostate cancer in white men in 1995 was approximately 0.1, 0.6, and 1 percent in men in their early 50s, 60s, and 70s, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/5\">",
"     5",
"    </a>",
"    ]. Although the incidence of new cases declines for men in their 80s, this almost certainly is attributable to the fact that fewer of these men have PSA-driven biopsies.",
"   </p>",
"   <p>",
"    The prevalence of malignancy based upon histologic examination of the prostate from men without clinical evidence of prostate cancer is much higher than the rate of clinically diagnosed disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/6\">",
"     6",
"    </a>",
"    ]. Although the reported prevalence rates for occult prostate cancer have varied substantially in different studies, the prevalence increased dramatically with age in all studies.",
"   </p>",
"   <p>",
"    The widespread prevalence of occult prostate cancer in older men and the dramatic increase with age are illustrated by a review of autopsy studies conducted in multiple countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      20 to 30 years, 2 to 8 percent of men with occult cancer",
"     </li>",
"     <li>",
"      31 to 40 years, 9 to 31 percent",
"     </li>",
"     <li>",
"      41 to 50 years, 3 to 43 percent",
"     </li>",
"     <li>",
"      51 to 60 years, 5 to 46 percent",
"     </li>",
"     <li>",
"      61 to 70 years, 14 to 70 percent",
"     </li>",
"     <li>",
"      71 to 80 years, 31 to 83 percent",
"     </li>",
"     <li>",
"      81 to 90 years, 40 to 73 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The variability between reports may reflect differences in pathologic techniques, or geographic differences due to environmental or ethnic factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETHNICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate cancer is more common in black than white or Hispanic men, perhaps related to a combination of dietary",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    genetic factors (",
"    <a class=\"graphic graphic_figure graphicRef62493 \" href=\"mobipreview.htm?43/37/44637\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/5,7-9\">",
"     5,7-9",
"    </a>",
"    ]. The annualized average incidence rates for men in their early 70s per 100,000 population is approximately 1600, 1000, and 700 for African-Americans, whites, and Asian-Americans, respectively. Although incidence rates in Native Americans are even lower than in Asian-Americans, ascertainment biases prevent credible comparisons.",
"   </p>",
"   <p>",
"    In addition to higher incidence rates, the age of onset in African-American men is earlier than for comparative groups. In a multi-institutional series of over 12,000 cases, 8.3 percent of blacks and 3.3 percent of whites were less than 50 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many studies have found that African-American men also have higher serum PSA levels, worse Gleason scores, and more advanced stage of disease at the time of diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. In the population-based Prostate Cancer Outcomes Study, the increased risk of advanced stage disease persisted in African-American men, even after adjustment for socioeconomic, clinical, and pathologic variables [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/11\">",
"     11",
"    </a>",
"    ]. One report found that African-American men diagnosed at an early stage still had a higher than expected rate of biochemical recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Poor health literacy has been implicated as a factor for advanced stage at presentation, irrespective of race [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/15\">",
"     15",
"    </a>",
"    ]. Also of interest, African-American men aged 60 and older (but not other age groups) with clinically localized prostate cancer received aggressive treatment significantly less often than either Caucasian or Hispanic men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/16\">",
"     16",
"    </a>",
"    ]. Similar results have been noted by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/17\">",
"     17",
"    </a>",
"    ]. The reasons for the differences in care received are not completely known but when stratified by pretreatment stage, grade, and PSA, the results of most studies do not support differences in outcome for African-American men as compared to Caucasians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/13,17-19\">",
"     13,17-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENETIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is evidence that prostate cancer has a strong genetic component, identifying specific genes that underlie the disease has proven challenging. Research has suggested the involvement of various genes, but results have been inconsistent across studies.",
"   </p>",
"   <p>",
"    Evidence supporting the role of genetic factors comes from studies of relatives of patients with prostate cancer, from genome-wide association studies, and from studies in patients with abnormalities in known cancer-associated genes such as BRCA2 and BRCA1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Family studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of prostate cancer is increased approximately twofold in men with one or more affected first-degree relatives (brother, father) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/20-24\">",
"     20-24",
"    </a>",
"    ]. There is a trend toward a further increased risk with a greater number of affected family members; men with two or three affected first-degree relatives had a 5- and 11-fold increased risk of prostate cancer, respectively, in one case control study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/21\">",
"     21",
"    </a>",
"    ]. Early age of onset in a family member also increases the risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/21-25\">",
"     21-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional evidence comes from a study of 45,000 Scandinavian twin pairs; concordance for cancer in identical twins was higher for prostate cancer than either breast or colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/26\">",
"     26",
"    </a>",
"    ]. This study estimated that as much as 42 percent of the risk of prostate cancer could be explained by heritable factors.",
"   </p>",
"   <p>",
"    In addition to affecting the risk of developing prostate cancer, genetic factors may influence the prognosis in men who do develop prostate cancer. In a Swedish study based upon 610 men with prostate cancer whose fathers also had prostate cancer, the survival of sons correlated that of their fathers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/27\">",
"     27",
"    </a>",
"    ]. When fathers survived for five years or more, the hazard ratio for death in their sons was 0.62 (95% CI 0.41-0.94), compared with those whose fathers had survived fewer than 24 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genome-wide association studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genome-wide association studies have identified alleles that are associated with an increased susceptibility to prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/28-37\">",
"     28-37",
"    </a>",
"    ]. The studies rely upon the presence of genetic variations, known as single nucleotide polymorphisms (SNPs). This approach has identified multiple foci in the 8q24 region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/28-35\">",
"     28-35",
"    </a>",
"    ] and the 17q region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], as well as other in chromosomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This approach is illustrated by a study that utilized 2893 Swedish men with prostate cancer and 1781 controls. The risk of prostate cancer was evaluated using a panel of five SNPs from three loci in 8q24, as well as single sites in 17q12 and 17q24.3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/37\">",
"     37",
"    </a>",
"    ]. Although the increased risk was relatively limited if any one of these SNPs was present (risk ratios [RR] 1.22 to 1.53), the risk increased dramatically if four of the five SNPs were present (RR 4.47, 95% CI 2.93 to 6.80). The risk was further increased if four or five of the SNPs were present and the subject had a family history of prostate cancer in a first-degree relative (RR 9.46, 95% CI 3.62 to 24.72).",
"   </p>",
"   <p>",
"    Despite the association of these genetic variants with the development of prostate cancer, none of the five was significantly associated with prognostic parameters in men with prostate cancer (Gleason score, serum PSA level at diagnosis, age). Although the information from a panel of these markers may be useful in identifying men who are at high risk for prostate cancer, additional prospective evaluations are necessary to establish the utility of this approach in additional populations.",
"   </p>",
"   <p>",
"    Although the SNPs are not necessarily within a known gene, they can be used to identify candidate genes that require further confirmation. Among the genes that have been suggested in this way are HOXB13, MSMB (beta-microseminoprotein), LMTK2, KLK3, CPNE3, IL16, CDH13, and HNF1B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/34,35,38\">",
"     34,35,38",
"    </a>",
"    ]. Genes identified through such genome wide association studies may eventually have a role in prostate cancer screening or as therapeutic targets. Alternatively, given the increasingly appreciated complexity of the non-coding genome, it is also plausible that these SNPs affect non-coding RNA expression in ways that are yet to be fully appreciated.",
"   </p>",
"   <p>",
"    Limitations in genetic screening should also be noted. Limited studies in various ethnic groups have been reported outside of the 8q24 region, and significant variation in the contribution of various SNPs to prostate cancer risk in various ethnic groups would not be unexpected. Lack of current \"risk-SNPs\" cannot be equated to lower risk, as a number of unidentified genetic factors may contribute to risk in a meaningful way.",
"   </p>",
"   <p>",
"    Deletion of sequences from chromosome 8p is a common event in the genome of prostate tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/39\">",
"     39",
"    </a>",
"    ]. Results from genetic linkage studies have also provided some evidence that germline 8p alterations may be linked to hereditary prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Whether there is a linkage between the germline and somatic genetic changes has yet to be conclusively demonstrated.",
"   </p>",
"   <p>",
"    These genome association studies provide evidence supporting the genetic complexity of prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/42\">",
"     42",
"    </a>",
"    ]. When multiple SNPs are considered in aggregate, these studies have a predictive power for prostate cancer that appears to be similar to that of serum PSA. Additional studies will be required to determine whether they can be combined with PSA levels and other clinical factors (ie, age, race, family history, prior biopsies) in identifying men who are at particularly high risk of being diagnosed with prostate cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetic environmental interaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potentially unique genetic-environmental interaction has been identified involving the ribonuclease L (RNAseL) gene locus. Particular germline variants of RNAseL are associated with decreased function of this enzyme, which is implicated in certain anti-viral immune responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prostate tissue from individuals with this particular genotype contains the previously undescribed xenotropic murine leukemia virus-related retrovirus (XMRV), which is highly homologous to a known murine leukemia-inducing retrovirus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'XMRV virus'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Gene-environment interactions influencing prostate cancer risk have also been demonstrated between a key antioxidant enzyme, manganese superoxide dismutase (MnSOD), and plasma antioxidant levels. Certain polymorphisms of MnSOD are associated with lower enzymatic activity as compared to others. When these genetic variants were examined in relationship to prostate cancer risk, no correlation was found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/46\">",
"     46",
"    </a>",
"    ]. However, after consideration of plasma antioxidant levels, a strong relationship was apparent, indicating that the MnSOD polymorphisms conferred an increased risk of prostate cancer only to men with lower levels of plasma antioxidants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     BRCA2 and BRCA1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of BRCA1 or BRCA2 mutations increases the risk of developing prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/47-52\">",
"     47-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an example, in a cohort study that involved 3728 men from 173 breast-ovarian cancer families with BRCA2 mutations identified at 20 centers in Europe and North America, the estimated relative risk (RR) of prostate cancer among BRCA2 carriers was 4.7-fold greater than controls (95% CI, 3.48-6.22) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      BRCA1 mutations may cause a lesser increase in risk for prostate cancer. In a multinational cohort study of 11,847 individuals with BRCA1 mutations, the risk of prostate cancer was elevated 1.8-fold in men under the age of 65, but the increase was not observed in older men [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prostate cancer in men with BRCA2 mutations appears to be associated with a higher Gleason score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/52,53\">",
"     52,53",
"    </a>",
"    ] and a substantially worse prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. In a study from Iceland that included 30 men with a 999 del5 mutation in BRCA2, prostate cancer was diagnosis at earlier age (69 versus 74 years) and was associated with a significantly shorter survival (2.1 versus 12.4 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/54\">",
"     54",
"    </a>",
"    ]. Similarly, in a multinational cohort study of men with prostate cancer that included 183 men from known BRCA2 families and 119 from BRCA1 families, those from BRCA2 families had a significantly shorter survival (4.0 versus 8.0 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The observational IMPACT study is looking at the role of PSA screening in patients with BRCA1 or BRCA2 mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/58\">",
"     58",
"    </a>",
"    ]. A preliminary report from this study found that 36 percent of BRCA1 carriers, 45 percent of BRCA2 carriers, and 28 percent of controls had prostate cancer, when biopsies were performed based upon a criterion of PSA &ge;3.0",
"    <span class=\"nowrap\">",
"     ng/ml.",
"    </span>",
"    Furthermore, 45 percent of the cases of prostate cancer in",
"    <span class=\"nowrap\">",
"     BRCA1/2",
"    </span>",
"    carriers had a Gleason score &ge;7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the overall risk of prostate cancer before the age of 50 is low, and there is no evidence that early detection through screening improves survival in any population, guidelines from ASCO suggest that men with inherited mutations begin screening for prostate cancer prior to age 50 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/60\">",
"     60",
"    </a>",
"    ]. Guidelines from the National Comprehensive Cancer Network (NCCN) recommend that the risks and benefits of prostate cancer screening be discussed at age 40 in this high risk group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=see_link\">",
"     \"Screening for prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=see_link\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=see_link\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20799858\">",
"    <span class=\"h2\">",
"     HOXB13",
"    </span>",
"    &nbsp;&mdash;&nbsp;The homeobox B13 (HOXB13) gene codes for a transcription factor that is important in prostate development. The G84E variant of the homeobox B13 (HOXB13) gene was identified by sequencing of the 17q21-22 region in four families with hereditary prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/62\">",
"     62",
"    </a>",
"    ]. Confirmatory studies in 5083 unrelated subjects with prostate cancer and 1401 controls found a 20-fold increase in the frequency of this variant in men with prostate cancer compared with those without prostate cancer (1.4 versus 0.1 percent). The molecular pathways and implications for the molecular pathogenesis of prostate cancer due to abnormalities in HOXB13 remain to be identified. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/9/30874?source=see_link&amp;anchor=H20797464#H20797464\">",
"     \"Molecular biology of prostate cancer\", section on 'HOXB13'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21977486\">",
"    <span class=\"h2\">",
"     Lynch syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lynch syndrome is an autosomal dominant disorder that is caused by a germline mutation in one of several DNA mismatch repair (MMR) genes. A study of 4127 men from familial cancer registries found that the cumulative risk of prostate cancer was significantly increased compared with the general population (6.3 versus 2.6 percent at age 60 years and 30 versus 18 percent at age 80 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIET",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comprehensive reviews of the association between intake of nutrients and the risk of prostate cancer are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. The most important components of the diet and the intake of some vitamin and mineral supplements will be discussed here. The use of some of these compounds as chemopreventive agents is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41736?source=see_link\">",
"     \"Chemoprevention strategies in prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Animal fat",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diet high in animal fat may be an important factor in the development of prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/66-70\">",
"     66-70",
"    </a>",
"    ]. In particular, intake of large amounts of alpha-linolenic acid and low amounts of linoleic acid appear to be associated with increased risk; this combination is common in red meat and some dairy products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/69-71\">",
"     69-71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vegetables",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diet low in vegetables may be another risk factor for prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/67,72,73\">",
"     67,72,73",
"    </a>",
"    ]. A case-control study found a higher prostate cancer risk in men who consume less than 14 servings of vegetables weekly, compared with 28 or more servings (adjusted odds ratio 1.54) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, there was no association between fruit",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vegetable consumption and the risk of prostate cancer among 29,361 men in the screening arm of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, 1338 of whom developed prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/74\">",
"     74",
"    </a>",
"    ]. High intake of cruciferous vegetables (particularly broccoli and cauliflower) was associated with a significantly lower risk of extra-prostatic tumors (stage III or IV (",
"    <a class=\"graphic graphic_table graphicRef75565 graphicRef67222 \" href=\"mobipreview.htm?38/23/39294\">",
"     table 1A-B",
"    </a>",
"    )) at presentation. Because the PLCO trial controls for prostate cancer screening, these data may be viewed as a particularly important study of dietary habits and prostate cancer risk.",
"   </p>",
"   <p>",
"    Tomato-based products are rich in lycopene, which has potent anti-oxidant properties. Well-conducted cohort studies suggested that lycopene-containing foods lower the risk of prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/75\">",
"     75",
"    </a>",
"    ]. However, other studies have failed to show a relationship between serum lycopene levels and prostate cancer risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. A United States Food and Drug Administration evidence-based review concluded that there was no credible evidence to support an association between lycopene intake and a reduced risk of prostate cancer, and only limited evidence to support an association between tomato consumption and reduced prostate cancer risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/78\">",
"     78",
"    </a>",
"    ]. Additional studies are needed to explore this putative relationship.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Soy intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phytoestrogens (flavones, isoflavones, lignans) are naturally occurring plant compounds that have estrogen-like activity. Genistein and daidzein, the predominant isoflavones in human nutrition, are derived mainly from soybeans and other legumes.",
"   </p>",
"   <p>",
"    It is postulated that phytoestrogens such as those found in soy foods may reduce prostate cancer risk either via their inherent estrogenic properties (which favorably alters the hormonal milieu), or by inhibition of the enzyme 5-AR, which decreases concentrations of the more prostate-active androgen dihydrotestosterone. The higher intake of soy products among Asian men has been hypothesized to be one reason for the lower incidence of prostate cancer among these men.",
"   </p>",
"   <p>",
"    Although few human studies have been conducted, cohort studies have shown a modest protective benefit of soy intake on prostate cancer risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. A meta-analysis of two cohort and six case-control studies addressing the protective benefit of soy food intake on the risk of prostate cancer yielded an overall risk estimate of 0.70 (95% CI 0.59-0.83) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/82\">",
"     82",
"    </a>",
"    ]. The utility of soy protein as a chemopreventive agent is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41736?source=see_link\">",
"     \"Chemoprevention strategies in prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2001 meta-analysis based upon 235 studies that included over 117,000 cases failed to identify a consistent relationship between alcohol intake and prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/83\">",
"     83",
"    </a>",
"    ]. This issue was subsequently addressed in the prospective Prostate Cancer Prevention Trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/84\">",
"     84",
"    </a>",
"    ]. There was no association between alcohol consumption and prostate cancer risk in 10,660 men with no or moderate alcohol intake (0 to &lt;50",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"    However, among the 260 men consuming &ge;50",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (2.4 percent of the entire population), the relative risk of high-grade prostate cancer was 2.0 (95% CI 1.3-3.1).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26833126\">",
"    <span class=\"h2\">",
"     Coffee",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing consumption of coffee appears to be associated with a decreased risk of lethal prostate cancer (defined as fatal or metastatic). A prospective analysis of almost 48,000 men from the Health Professionals Follow-up Study identified 5035 men with confirmed prostate cancer, including 642 who died or had metastatic disease, identified over a 20 year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/85\">",
"     85",
"    </a>",
"    ]. The decrease in risk of lethal prostate cancer was inversely proportional to increases in coffee consumption (relative risk 0.44, 95% CI 0.22-0.75, for those drinking six or more cups of coffee per day), and the decreased risk was present after controlling for other known prostate cancer risk factors. The inverse relationship appeared to be related to coffee components other than caffeine; a similar level of protection was seen for those drinking regular and decaffeinated coffee.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Vitamin and mineral supplements",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Multivitamins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The regular use of multivitamins does not appear to affect the risk of early or localized prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/86\">",
"     86",
"    </a>",
"    ]. However, two reports have observed an increased risk of advanced or fatal prostate cancer in men using relatively large amounts of multivitamins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential relationship between the self-reported frequency of multivitamin use and prostate cancer was illustrated by a prospective study of 295,000 men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/86\">",
"     86",
"    </a>",
"    ]. Multivariate analyses showed no significant increase in the overall incidence of prostate cancer, regardless of the frequency of multivitamin use. However, there was an increase in both advanced and fatal cases of prostate cancer among men using multivitamins more than seven times per week compared to those using such vitamins less frequently or not at all (RR 1.32, 95% CI 1.04-1.67 and RR 1.98, 95% CI1.07-3.66, respectively).",
"   </p>",
"   <p>",
"    This increased risk of advanced or fatal prostate cancer may have been due to the increased use of multivitamins in men with symptoms of undiagnosed disease. Additional study of a possible relationship is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Folic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary supplementation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    was associated with an increased incidence of prostate cancer in a secondary analysis from the",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"      Aspirin",
"     </a>",
"     /Folate",
"    </span>",
"    Polyp Prevention Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As part of a trial to assess the chemoprevention of colorectal polyps, 34 histologically confirmed cases of prostate cancer were diagnosed among 643 evaluable men who had been randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    <span class=\"nowrap\">",
"     (1mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/88\">",
"     88",
"    </a>",
"    ]. At a median follow-up of seven years, the ten-year incidence of prostate cancer was significantly increased in those given folic acid (9.7 versus 3.3 percent with placebo, hazard ratio 2.63, 95% CI 1.23-5.65). However, there was no increase in the risk of prostate cancer among those with higher baseline dietary folate intake.",
"   </p>",
"   <p>",
"    The total number of cases of prostate cancer was limited in this trial, and additional studies are required to understand the relationship between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    and the development of prostate cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Selenium and vitamin E",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although observational studies and secondary analyses from a randomized trial suggested that increased intake of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitamin E was associated with a decreased risk of prostate cancer, results from large randomized trials specifically assessing these compounds as chemopreventive agents have provided no evidence of any decrease in prostate cancer risk, and in fact, there may be a statistically significant increased risk with vitamin E. These results are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41736?source=see_link&amp;anchor=H15#H15\">",
"     \"Chemoprevention strategies in prostate cancer\", section on 'Selenium'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41736?source=see_link&amp;anchor=H14#H14\">",
"     \"Chemoprevention strategies in prostate cancer\", section on 'Vitamin E'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Zinc",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least two studies have suggested an association between zinc supplement use and an increased risk of prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. In the Health Professionals Follow-Up Study, which included 46,974 American men, 2901 cases of prostate cancer were diagnosed over a 14 year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/90\">",
"     90",
"    </a>",
"    ]. Compared with nonusers, men who consumed over 100 mg of supplemental zinc daily had a 2.29-fold increased risk of prostate cancer; the RR was 2.37 in those who took zinc for 10 or more years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Calcium and vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;A link between intake of dairy products and calcium and a higher risk of prostate cancer risk has been suggested in many [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/92-96\">",
"     92-96",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. In a meta-analysis examining the association of dairy product and calcium intake and prostate cancer risk, men with the highest intake of dairy products (relative risk [RR] 1.11, 95% CI 1.0 to 1.22) and calcium (RR 1.39, 95% CI 1.09 to 1.77) were more likely to develop prostate cancer than those with the lowest intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epidemiologic studies suggest that the relationship between vitamin D levels and the incidence of prostate cancer is complex. Vitamin D deficiency has been suggested as a \"common pathway\" underlying the association of prostate cancer risk with other epidemiologic risk factors as well (eg, age, African-American race, and geographic area of residence) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/99\">",
"     99",
"    </a>",
"    ]. Others have shown a link between certain haplotypes of the vitamin D receptor, vitamin D levels, and the risk of prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/8,94\">",
"     8,94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, studies directly analyzing vitamin D levels and the risk of prostate cancer have not fully supported the relationship. Studies from Scandinavia, where there is a relatively high incidence of vitamin D deficiency, have suggested that there is an increased risk of prostate cancer in men with both the lowest and highest levels of vitamin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/100,101\">",
"     100,101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, where vitamin D deficiency is less common, studies have not clarified the relationship between vitamin D levels and the risk of prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/102\">",
"     102",
"    </a>",
"    ]. In a nested, case-control study from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening trial, baseline levels of serum vitamin D were correlated with the subsequent development of prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/103\">",
"     103",
"    </a>",
"    ]. There was no statistically significant trend in overall prostate cancer risk associated with the serum vitamin D levels, although higher levels of vitamin D were associated with increased aggressiveness in those men diagnosed with prostate cancer, as manifested by Gleason score &ge;7 or stage III or IV disease at diagnosis.",
"   </p>",
"   <p>",
"    The role of vitamin D in chemoprevention of prostate cancer is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41736?source=see_link&amp;anchor=H16#H16\">",
"     \"Chemoprevention strategies in prostate cancer\", section on 'Vitamin D analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     HORMONE LEVELS AND OBESITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum concentrations of androgens and insulin-like growth factor-I (IGF-I) have been studied as possible risk factors for prostate cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Sex hormones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have looked at the relationship between serum levels of various sex hormones and the risk of developing prostate cancer. The most definitive data regarding the relationship between serum sex hormone levels and prostate cancer come from a pooled analysis of 18 prospective trials, which included 3886 men with prostate cancer and 6438 controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/104\">",
"     104",
"    </a>",
"    ]. Serum concentrations of testosterone, dihydrotestosterone (DHT), and other active androgen derivatives obtained prior to diagnosis were NOT associated with an increased risk of subsequent prostate cancer. In addition, no association was seen with prediagnosis serum levels of estrogens (estradiol, free estradiol).",
"   </p>",
"   <p>",
"    In addition, testosterone supplementation as a treatment for hypogonadism does not appear to be associated with an increased risk of prostate cancer, although monitoring for prostate abnormalities is recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1545?source=see_link&amp;anchor=H17#H17\">",
"     \"Testosterone treatment of male hypogonadism\", section on 'Undesirable effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/13/4314?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of testosterone deficiency in elderly men\", section on 'Prostate cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A possible link between androgenic stimulation and prostate cancer provided the rationale for the Prostate Cancer Prevention Trial and the REDUCE Trial, which used",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    , respectively, to block the conversion of testosterone to its more active derivative DHT. The results and interpretation of this trial are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41736?source=see_link&amp;anchor=H6#H6\">",
"     \"Chemoprevention strategies in prostate cancer\", section on '5-Alpha reductase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Insulin and insulin-like growth factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have analyzed the relationship between insulin and insulin-like growth factor (IGF) and the subsequent development of prostate cancer.",
"   </p>",
"   <p>",
"    A meta-analysis based upon individual patient data from 3700 men with prostate cancer and 5200 controls found a modest increased risk of prostate cancer in those men with the highest circulating levels of IGF-I (odds ratio 1.38, 95% CI 1.19-1.60, for the highest versus lowest quintile) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/105\">",
"     105",
"    </a>",
"    ]. The association appeared strongest for low-grade, rather than high-grade, prostate cancers.",
"   </p>",
"   <p>",
"    Similarly, most [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/106-109\">",
"     106-109",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/110\">",
"     110",
"    </a>",
"    ] series support a relationship between higher serum insulin levels, waist-hip ratio (WHR, a marker of body fat distribution) and prostate cancer risk. In a representative case control study of Chinese men, those in the highest tertiles of WHR and serum insulin levels had an 8.55-fold higher risk of prostate cancer than men in the lowest tertiles of both factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple prospective cohort and case control studies have given conflicting results about the association between the incidence of prostate cancer and obesity as assessed by body mass index (BMI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/111\">",
"     111",
"    </a>",
"    ]. The most extensive data come from a 2006 meta-analysis that included information on over 68,000 men with prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/112\">",
"     112",
"    </a>",
"    ]. Overall, there was a statistically significant increase in prostate cancer with increasing BMI (relative risk [RR] 1.06 for each 5",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ).",
"    </span>",
"   </p>",
"   <p>",
"    There is a clear relationship between obesity and prostate cancer aggressiveness. In the meta-analysis, the increased risk was limited to patients with advanced disease and was not present in those with localized disease (RR 1.12 versus 0.96 for each 5",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/112\">",
"     112",
"    </a>",
"    ]. The relationship between obesity and prostate cancer aggressiveness has been subsequently identified in multiple additional studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/113-116\">",
"     113-116",
"    </a>",
"    ] and is more pronounced in African Americans compared with whites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the data linking body mass index and prostate cancer aggressiveness would suggest that regular physical activity may be beneficial, whether exercise protects against the development or progression of prostate cancer is uncertain. This issue was addressed in a study using data from the Health Professionals Follow-up Study, a cohort of 47,620 United States health professionals followed from 1986 to 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/117\">",
"     117",
"    </a>",
"    ]. There was no association overall between prostate cancer incidence and total, vigorous or nonvigorous physical activity in the entire population. However, men over the age of 65 who were in the highest category of vigorous activity (more than three hours per week of vigorous activity) had a significantly lower risk of advanced (RR 0.33, 95% CI 0.17 to 0.62) or fatal (RR 0.26, 95% CI 0.11 to 0.66) prostate cancer. Younger men derived no benefit. However, in all age groups, men with high levels of physical activity (more than 29 metabolic equivalent hours versus none) were less likely to be diagnosed with high-grade (Gleason score &ge;7) prostate cancers.",
"   </p>",
"   <p>",
"    Some (but not all) of the beneficial effects of exercise in older men may be related to sun exposure while exercising outdoors (see below). In a sample of men in this cohort, men who reported higher levels of physical activity had higher circulating levels of 25-hydroxyvitamin D [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/118\">",
"     118",
"    </a>",
"    ]. However, while both vigorous and nonvigorous activity were associated with higher vitamin D concentrations, only vigorous activity was associated with a lower risk of advanced prostate cancer.",
"   </p>",
"   <p>",
"    In contrast to these data, another report from the same investigators suggests that young lean men who are more physically active have an increased risk of developing metastatic disease and fatal prostate cancer if they had a high energy intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, although there are many benefits from regular physical exercise, it is not clear that a reduced incidence of prostate cancer is among them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     OTHER FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Infection and chronic inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different infectious etiologies have been postulated as contributory factors in the development of prostate cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Prostatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case-control and cohort studies, as well as two meta-analyses, suggest a significant but modest increase in the risk of prostate cancer in men with prostatitis (RR = 1.6) and in those with a history of syphilis or gonorrhea (RR = 1.4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/120,121\">",
"     120,121",
"    </a>",
"    ]. Despite a significant body of work relating inflammation to cancer, a cause and effect relationship has not been established between prostate cancer and prostatitis. Furthermore, PSA values can be elevated with prostatitis, leading to more prostate biopsies and a greater likelihood of making the diagnosis of cancer.",
"   </p>",
"   <p>",
"    As discussed in the introduction, ascertainment biases are significant in prostate cancer. Any factor associated with an elevation in the serum PSA would be expected to lead to more biopsies being performed, and consequently, more cancers being detected. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Trichomonas vaginalis infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case-control series from the Health Professionals Follow-up Study and the Physicians Health Study both have shown an increased incidence of seropositivity for antibodies against trichomonas vaginalis in men who subsequently are diagnosed with prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/122,123\">",
"     122,123",
"    </a>",
"    ]. This association was more pronounced in those with more advanced or higher Gleason grade tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     XMRV virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;XMRV is a gammaretrovirus, and other members of this group are known to be oncogenic in various rodents and primates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/124\">",
"     124",
"    </a>",
"    ]. The xenotropic murine leukemia virus-related virus (XMRV) was postulated as a causative agent for prostate cancer in some men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/45,124\">",
"     45,124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, subsequent studies did not confirm these findings and indicate that contamination with murine DNA may have contributed to anomalous results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/125-127\">",
"     125-127",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12086944\">",
"    <span class=\"h2\">",
"     Environmental carcinogens",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Agent Orange",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to Agent Orange, an herbicide defoliant sprayed extensively in Vietnam between 1965 and 1971 that contained dioxins, appears to be associated with an increased incidence of prostate cancer. The cases of prostate cancer arising in those exposed to Agent Orange appear to be more aggressive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/128-130\">",
"     128-130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial studies that analyzed a possible relationship between exposure to Agent Orange and the subsequent development of prostate cancer yielded conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/128,131-133\">",
"     128,131-133",
"    </a>",
"    ]. These studies were limited by relatively limited numbers of patients, the young age of the cohorts involved, and potential biases of recall about Agent Orange exposure.",
"   </p>",
"   <p>",
"    The most extensive study analyzed the history of Agent Orange exposure in a cohort of 13,124 Vietnam veterans from the Veterans Administration electronic medical record database [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/134\">",
"     134",
"    </a>",
"    ]. Prostate cancer developed significantly more frequently in those exposed to Agent Orange (239 of 6214 men exposed [3.8 percent] versus 124 of 6930 unexposed [2.0 percent]). Among those with prostate cancer, a Gleason score of 8 to 10 was significantly more frequent in those exposed to Agent Orange, as was the likelihood of having metastatic disease at presentation (21.8 versus 10.5 and 13.4 versus 4 percent, respectively). There was no difference in the history of PSA screening in those with and without Agent Orange exposure, and a history of Agent Orange exposure was established prior to the diagnosis of prostate cancer in all cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12086956\">",
"    <span class=\"h3\">",
"     Chlordecone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chlordecone is an organochlorine insecticide with estrogenic properties, which was widely used in the West Indies from 1973 to 1993. Chlordecone has been shown to be carcinogenic in laboratory animal models. A case control series compared plasma levels of chlordecone and exposure history in 623 men with prostate cancer and 671 controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/135\">",
"     135",
"    </a>",
"    ]. There was a statistically significant increase in the incidence of prostate cancer, which was related to the measured level of this agent as well as exposure history. The mechanisms underlying these observations require further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Use of NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intake of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other nonsteroidal antiinflammatory drugs (NSAIDs) has been associated with a decreased risk of some cancers, particularly colorectal cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22666?source=see_link\">",
"     \"NSAIDs (including aspirin): Role in prevention of cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An inverse association between long-term NSAID use and prostate cancer risk has also been suggested, although the magnitude of the risk reduction is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/136-139\">",
"     136-139",
"    </a>",
"    ]. The largest cohort study examined the association between NSAID use and prostate cancer incidence among 70,144 men in the American Cancer Society Cancer Prevention Study II Nutrition Cohort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/136\">",
"     136",
"    </a>",
"    ]. Information on use of NSAID was obtained from questionnaires completed at study entry and five to six years later. Over a nine-year follow-up period, 4853 cases of incident prostate cancer were diagnosed. Long duration regular use (30 or more pills per month for five or more years) of either NSAIDs (relative risk [RR] 0.82, 95% CI 0.71 to 0.94) or adult-strength",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (RR 0.85, 95% CI 0.73 to 0.99) was associated with a significantly reduced incidence of prostate cancer.",
"   </p>",
"   <p>",
"    On the other hand, a meta-analysis that included 12 published case-control or cohort studies concluded that there may be a modest protective effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (odds ratio 0.9, 95% CI 0.82-0.99) but that the data for nonaspirin NSAIDs were too heterogeneous for meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/140\">",
"     140",
"    </a>",
"    ]. The lack of prospective trials makes it difficult to draw conclusions in this area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple observational studies have raised the possibility that use of statins may affect the overall risk of cancer and of specific cancers. However, meta-analyses of randomized trials have consistently shown no effect of statins on cancer incidence or cancer mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10230?source=see_link&amp;anchor=H3#H3\">",
"     \"Statins: Possible noncardiovascular benefits\", section on 'Cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several large studies have looked specifically on the impact of statin use on the risk of prostate cancer. Results of these analyses suggest that statin use reduces the risk of advanced, clinically significant disease, although there are conflicting data regarding the effect on overall incidence of prostate cancer. A meta-analysis that included data from six randomized trials and 13 observational studies found no relationship between statin use and the incidence of prostate cancer either in six randomized trials or 13 observational studies (relative risks [RRs] 1.06, 95% CI 0.93-1.20 and 0.89, 95% CI 0.65-1.24, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/141\">",
"     141",
"    </a>",
"    ]. However, statin use was associated with a decreased risk of advanced prostate cancer (RR 0.77, 95% CI 0.64-0.93).",
"   </p>",
"   <p>",
"    The variable results are illustrated by two large studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Health Professionals Follow-up Study identified 2579 cases of prostate cancer, which included 316 with regionally invasive, metastatic, or fatal disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/142\">",
"       142",
"      </a>",
"      ]. There was no association between statin use and the overall risk of prostate cancer (RR 0.96, 95% CI 0.85-1.09). However, multivariate analysis found a significant decrease in the risk of advanced disease after controlling for known risk factors (RR 0.51, 95% CI 0.30-0.86). Furthermore, the decrease in risk was more pronounced when the duration of statin use was considered.",
"     </li>",
"     <li>",
"      In a retrospective study of over 55,000 men taking either a statin or an antihypertensive medication, there was a statistically significant 31 percent reduction in the incidence of prostate cancer compared to men on an antihypertensive medication (HR 0.69, 95% CI 0.52-0.90) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/143\">",
"       143",
"      </a>",
"      ]. The risk reduction was greater for those with high-grade prostate cancer (HR 0.40, 95% CI 0.24-0.65) compared with those with low-grade lesions (HR 0.86, 95% CI 0.62-1.20).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Vasectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether a prior vasectomy also increases a man's risk of getting prostate cancer has been controversial. Although earlier studies suggested that vasectomy may slightly increase the risk of prostate cancer, an effect that appeared to increase with time after the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/144\">",
"     144",
"    </a>",
"    ], more recent data support the absence of a relationship between vasectomy and prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/145-147\">",
"     145-147",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Ejaculatory frequency",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between ejaculatory frequency and a lower risk of prostate cancer has been suggested in two case control studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study which compared men under the age of 70 who had prostate cancer and age-matched controls, men who had five or more ejaculations per week while in their 20s (but not their 30s or 40s) had a significantly lower risk of prostate cancer (odds ratio 0.66) than those who had fewer ejaculations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/148\">",
"       148",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A report from the Health Professionals Follow-up Study compared men who developed prostate cancer (n = 1449) and controls of a similar age group who had similar ejaculatory frequency but no prostate cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/149\">",
"       149",
"      </a>",
"      ]. Although most categories of ejaculation frequency were unrelated to prostate cancer risk, men who reported 20 or more monthly ejaculations during their 40s, within the past year, or averaged across a lifetime had a significantly lower risk of prostate cancer compared to men having four to seven ejaculations per month (odds ratios of 0.67, 0.49, and 0.67, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The validity of this relationship has been called into question because of the lack of association of prostate cancer with ejaculation frequency in older men and the fact that other studies have failed to show a protective effect from being married or having more sexual partners [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/120\">",
"     120",
"    </a>",
"    ]. Moreover, the problem of recall bias also casts doubt on the interpretation of studies that use this methodology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Ultraviolet light exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one case control study exposure to ultraviolet (UV) light had a protective effect on the development of prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/150\">",
"     150",
"    </a>",
"    ]. Furthermore, cases with low UV exposure developed at a younger median age (68 versus 72 years old). A similar associated has been reported by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/151-153\">",
"     151-153",
"    </a>",
"    ]. It is not clear that any exposure pattern can successfully reduce the risk of prostate cancer without increasing the risk for basal cell skin cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/153\">",
"     153",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/39/14970?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\", section on 'UV light exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the mechanism underlying this association is unclear, involvement of vitamin D",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    its receptor has been hypothesized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/153\">",
"     153",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Calcium and vitamin D'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Diagnostic radiologic procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible increase in risk of prostate cancer due to diagnostic radiologic procedures was suggested in a case control series of 431 men diagnosed at age 60 years or less and 409 matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/154\">",
"     154",
"    </a>",
"    ]. Procedures associated with an increased risk included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema and hip or pelvis x-rays at least five years prior to the diagnosis of prostate cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     EBRT for rectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although external beam radiation therapy (EBRT) for prostate cancer is associated with an increased risk of rectal cancer, RT for rectal cancer has not been associated with an increased risk of subsequent prostate cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=see_link&amp;anchor=H14#H14\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\", section on 'Other risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study based upon the Surveillance, Epidemiology and End Results (SEER) database, the risk of prostate cancer was decreased by 72 percent in 1572 men who had previously received EBRT as a component of their treatment for rectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/155\">",
"     155",
"    </a>",
"    ]. In contrast, the incidence or prostate cancer among 3114 men with rectal cancer and 24,578 with colon cancer who were treated without RT was similar to that expected in the general population.",
"   </p>",
"   <p>",
"    In contrast to the findings from the SEER study, a decrease in the incidence of prostate cancer was not observed in two Swedish studies of men receiving EBRT for rectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/156\">",
"     156",
"    </a>",
"    ]. A possible explanation for the discrepant findings is that substantially lower doses of EBRT were used in the Swedish studies (25 Gy in five fractions versus typical regimens of 45 to 54 Gy in 1.8 to 2 Gy fractions in the United States).",
"   </p>",
"   <p>",
"    At least two mechanisms could contribute to a reduction in the apparent risk of prostate cancer following EBRT for pelvic cancer. Incidental RT to the prostate may have a biologic effect, reducing or sterilizing subclinical areas of disease. Alternatively inadvertent irradiation of the prostate can decrease the serum PSA, which would diminish the diagnosis of prostate cancer without affecting its incidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/157,158\">",
"     157,158",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     USING RISK FACTORS TO ESTIMATE PROSTATE CANCER RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;An online prostate cancer risk calculator has been developed (and independently validated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/159\">",
"     159",
"    </a>",
"    ]) in an attempt to permit men being screened for prostate cancer to estimate their risk of being diagnosed with the disease on prostate biopsy based upon certain risk factors such as age, serum PSA level, the results of digital rectal examination (DRE), family history, race, and prior history of a negative biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/52/31562/abstract/160\">",
"     160",
"    </a>",
"    ]. The risk estimates are based on data from over 5000 men who were enrolled in the control group of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    prostate cancer prevention trial, and they apply only to men age 50 and older, without a prior diagnosis of prostate cancer, who have undergone screening with serum PSA and DRE within the last year. The utility of risk calculators such as these is limited as they do not provide guidance as to what level of risk should prompt prostate biopsy. Regardless, they are useful in terms of communicating risk to patients and helping to understand that risk is a continuum of PSA level.",
"   </p>",
"   <p>",
"    Prostate cancer screening and prostate cancer chemoprevention are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41736?source=see_link\">",
"     \"Chemoprevention strategies in prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=see_link\">",
"     \"Screening for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/55/38770?source=see_link\">",
"       \"Patient information: Prostate cancer screening (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most important risk factor for the development of prostate cancer is increasing age. Although prostate cancer is rare in men less than 40 years, its incidence increases progressively thereafter. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epidemiologic studies have shown that the risk of prostate cancer is higher in African-Americans compared with other ethnic groups. Prostate cancer occurs at an earlier age in these individuals and is associated with a more aggressive clinical course than in other ethnic groups. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Ethnicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic factors, such as mutations in BRCA1 and BRCA2, appear to play an important role in the development certain prostate cancers. Genome wide association studies are being used to identify other genetic factors that influence the risk of prostate cancer in the broader population. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Genetic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other factors, such as diet, hormone levels, and obesity, have been studied with the goal of developing strategies to reduce the risk of prostate cancer. Although such factors may have some effect on incidence, their role appears limited. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diet'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Hormone levels and obesity'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41736?source=see_link\">",
"       \"Chemoprevention strategies in prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/2\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/3\">",
"      Gr&ouml;nberg H. Prostate cancer epidemiology. Lancet 2003; 361:859.",
"     </a>",
"    </li>",
"    <li>",
"     SEER Cancer Statistics Review, 1973-1999 file://seer.cancer.gov/csr/1973_1999/ (Accessed on February 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/5\">",
"      Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/6\">",
"      Delongchamps NB, Singh A, Haas GP. The role of prevalence in the diagnosis of prostate cancer. Cancer Control 2006; 13:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/7\">",
"      Baquet CR, Horm JW, Gibbs T, Greenwald P. Socioeconomic factors and cancer incidence among blacks and whites. J Natl Cancer Inst 1991; 83:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/8\">",
"      Ingles SA, Coetzee GA, Ross RK, et al. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res 1998; 58:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/9\">",
"      Platz EA, Rimm EB, Willett WC, et al. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 2000; 92:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/10\">",
"      Parker PM, Rice KR, Sterbis JR, et al. Prostate cancer in men less than the age of 50: a comparison of race and outcomes. Urology 2011; 78:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/11\">",
"      Hoffman RM, Gilliland FD, Eley JW, et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2001; 93:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/12\">",
"      Powell IJ, Banerjee M, Sakr W, et al. Should African-American men be tested for prostate carcinoma at an earlier age than white men? Cancer 1999; 85:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/13\">",
"      Cross CK, Shultz D, Malkowicz SB, et al. Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. J Clin Oncol 2002; 20:2863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/14\">",
"      Hamilton RJ, Aronson WJ, Presti JC Jr, et al. Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer 2007; 110:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/15\">",
"      Bennett CL, Ferreira MR, Davis TC, et al. Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol 1998; 16:3101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/16\">",
"      Harlan LC, Potosky A, Gilliland FD, et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 2001; 93:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/17\">",
"      Krupski TL, Kwan L, Afifi AA, Litwin MS. Geographic and socioeconomic variation in the treatment of prostate cancer. J Clin Oncol 2005; 23:7881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/18\">",
"      Iselin CE, Box JW, Vollmer RT, et al. Surgical control of clinically localized prostate carcinoma is equivalent in African-American and white males. Cancer 1998; 83:2353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/19\">",
"      Eastham JA, Kattan MW. Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer. J Urol 2000; 163:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/20\">",
"      Whittemore AS, Wu AH, Kolonel LN, et al. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol 1995; 141:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/21\">",
"      Steinberg GD, Carter BS, Beaty TH, et al. Family history and the risk of prostate cancer. Prostate 1990; 17:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/22\">",
"      Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer 2003; 97:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/23\">",
"      Bruner DW, Moore D, Parlanti A, et al. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer 2003; 107:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/24\">",
"      Hemminki K, Czene K. Age specific and attributable risks of familial prostate carcinoma from the family-cancer database. Cancer 2002; 95:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/25\">",
"      Valeri A, Cormier L, Moineau MP, et al. Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives. J Urol 2002; 168:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/26\">",
"      Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/27\">",
"      Hemminki K, Ji J, F&ouml;rsti A, et al. Concordance of survival in family members with prostate cancer. J Clin Oncol 2008; 26:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/28\">",
"      Amundadottir LT, Sulem P, Gudmundsson J, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006; 38:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/29\">",
"      Freedman ML, Haiman CA, Patterson N, et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A 2006; 103:14068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/30\">",
"      Gudmundsson J, Sulem P, Manolescu A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007; 39:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/31\">",
"      Haiman CA, Patterson N, Freedman ML, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007; 39:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/32\">",
"      Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/33\">",
"      Zheng SL, Sun J, Cheng Y, et al. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst 2007; 99:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/34\">",
"      Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008; 40:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/35\">",
"      Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/36\">",
"      Gudmundsson J, Sulem P, Steinthorsdottir V, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007; 39:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/37\">",
"      Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/38\">",
"      Sun J, Zheng SL, Wiklund F, et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet 2008; 40:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/39\">",
"      Dong JT. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev 2001; 20:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/40\">",
"      Chang BL, Liu W, Sun J, et al. Integration of somatic deletion analysis of prostate cancers and germline linkage analysis of prostate cancer families reveals two small consensus regions for prostate cancer genes at 8p. Cancer Res 2007; 67:4098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/41\">",
"      Xu J, Dimitrov L, Chang BL, et al. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 2005; 77:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/42\">",
"      Zheng SL, Sun J, Wiklund F, et al. Genetic variants and family history predict prostate cancer similar to prostate-specific antigen. Clin Cancer Res 2009; 15:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/43\">",
"      Casey G, Neville PJ, Plummer SJ, et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002; 32:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/44\">",
"      Li H, Tai BC. RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis. Clin Cancer Res 2006; 12:5713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/45\">",
"      Urisman A, Molinaro RJ, Fischer N, et al. Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2006; 2:e25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/46\">",
"      Li H, Kantoff PW, Giovannucci E, et al. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 2005; 65:2498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/47\">",
"      Thompson D, Easton DF, Breast Cancer Linkage Consortium. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/48\">",
"      Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/49\">",
"      Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999; 91:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/50\">",
"      Edwards SM, Kote-Jarai Z, Meitz J, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003; 72:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/51\">",
"      Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006; 98:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/52\">",
"      Agalliu I, Gern R, Leanza S, Burk RD. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clin Cancer Res 2009; 15:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/53\">",
"      Mitra A, Fisher C, Foster CS, et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 2008; 98:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/54\">",
"      Tryggvad&oacute;ttir L, Vidarsd&oacute;ttir L, Thorgeirsson T, et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007; 99:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/55\">",
"      Narod SA, Neuhausen S, Vichodez G, et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 2008; 99:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/56\">",
"      Edwards SM, Evans DG, Hope Q, et al. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer 2010; 103:918.",
"     </a>",
"    </li>",
"    <li>",
"     Castro, E, et al. Effect of germ-line BRCA mutations in biochemical relapse and survival after treatment for localized prostate cancer. J Clin Oncol 2013; 31: (suppl 6; abstr 29).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/58\">",
"      Edgerton N, Sirintrapun SJ, Munoz M, et al. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 24 cases. Int J Urol 2011; 18:49.",
"     </a>",
"    </li>",
"    <li>",
"     Eeles RA, et al. Identification of men with a genetic predisposition to prostate cancer: Targeted screening in men at higher genetic risk and controls&mdash;The IMPACT study. J Clin Oncol 2013; 31: (suppl 6; abstr 12).",
"    </li>",
"    <li>",
"     Genitourinary cancer syndromes. In: ASCO Curriculum: Cancer Genetics and Cancer Predisposition Testing, 2nd, Offitt K, Garber J, Grady M (Eds), ASCO Publishing, Alexandria 2004. p.10.",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/62\">",
"      Ewing CM, Ray AM, Lange EM, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 2012; 366:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/63\">",
"      Raymond VM, Mukherjee B, Wang F, et al. Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/64\">",
"      Schulman CC, Ekane S, Zlotta AR. Nutrition and prostate cancer: evidence or suspicion? Urology 2001; 58:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/65\">",
"      Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression. J Clin Oncol 2005; 23:8152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/66\">",
"      Kolonel LN, Nomura AM, Cooney RV. Dietary fat and prostate cancer: current status. J Natl Cancer Inst 1999; 91:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/67\">",
"      Colli JL, Colli A. International comparisons of prostate cancer mortality rates with dietary practices and sunlight levels. Urol Oncol 2006; 24:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/68\">",
"      Giovannucci E, Rimm EB, Colditz GA, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 1993; 85:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/69\">",
"      Sinha R, Park Y, Graubard BI, et al. Meat and meat-related compounds and risk of prostate cancer in a large prospective cohort study in the United States. Am J Epidemiol 2009; 170:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/70\">",
"      Gann PH, Hennekens CH, Sacks FM, et al. Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst 1994; 86:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/71\">",
"      Allen NE, Key TJ, Appleby PN, et al. Animal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2008; 98:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/72\">",
"      Cohen JH, Kristal AR, Stanford JL. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 2000; 92:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/73\">",
"      Jian L, Du CJ, Lee AH, Binns CW. Do dietary lycopene and other carotenoids protect against prostate cancer? Int J Cancer 2005; 113:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/74\">",
"      Kirsh VA, Peters U, Mayne ST, et al. Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst 2007; 99:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/75\">",
"      Giovannucci E, Rimm EB, Liu Y, et al. A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 2002; 94:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/76\">",
"      Peters U, Leitzmann MF, Chatterjee N, et al. Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2007; 16:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/77\">",
"      Kristal AR, Till C, Platz EA, et al. Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2011; 20:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/78\">",
"      Kavanaugh CJ, Trumbo PR, Ellwood KC. The U.S. Food and Drug Administration's evidence-based review for qualified health claims: tomatoes, lycopene, and cancer. J Natl Cancer Inst 2007; 99:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/79\">",
"      Kolonel LN, Hankin JH, Whittemore AS, et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev 2000; 9:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/80\">",
"      Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 1998; 9:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/81\">",
"      Kurahashi N, Iwasaki M, Inoue M, et al. Plasma isoflavones and subsequent risk of prostate cancer in a nested case-control study: the Japan Public Health Center. J Clin Oncol 2008; 26:5923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/82\">",
"      Yan L, Spitznagel EL. Meta-analysis of soy food and risk of prostate cancer in men. Int J Cancer 2005; 117:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/83\">",
"      Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. A meta-analysis of alcohol drinking and cancer risk. Br J Cancer 2001; 85:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/84\">",
"      Gong Z, Kristal AR, Schenk JM, et al. Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer 2009; 115:3661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/85\">",
"      Wilson KM, Kasperzyk JL, Rider JR, et al. Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. J Natl Cancer Inst 2011; 103:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/86\">",
"      Lawson KA, Wright ME, Subar A, et al. Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst 2007; 99:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/87\">",
"      Stevens VL, McCullough ML, Diver WR, et al. Use of multivitamins and prostate cancer mortality in a large cohort of US men. Cancer Causes Control 2005; 16:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/88\">",
"      Figueiredo JC, Grau MV, Haile RW, et al. Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst 2009; 101:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/89\">",
"      Cole BF, Baron JA, Sandler RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 2007; 297:2351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/90\">",
"      Leitzmann MF, Stampfer MJ, Wu K, et al. Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst 2003; 95:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/91\">",
"      Zhang Y, Coogan P, Palmer JR, et al. Vitamin and mineral use and risk of prostate cancer: the case-control surveillance study. Cancer Causes Control 2009; 20:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/92\">",
"      Giovannucci E, Liu Y, Stampfer MJ, Willett WC. A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/93\">",
"      Chan JM, Giovannucci E, Andersson SO, et al. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 1998; 9:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/94\">",
"      Ma J, Stampfer MJ, Gann PH, et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 1998; 7:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/95\">",
"      Gao X, LaValley MP, Tucker KL. Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. J Natl Cancer Inst 2005; 97:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/96\">",
"      Mitrou PN, Albanes D, Weinstein SJ, et al. A prospective study of dietary calcium, dairy products and prostate cancer risk (Finland). Int J Cancer 2007; 120:2466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/97\">",
"      Severi G, English DR, Hopper JL, Giles GG. Re: Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. J Natl Cancer Inst 2006; 98:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/98\">",
"      Koh KA, Sesso HD, Paffenbarger RS Jr, Lee IM. Dairy products, calcium and prostate cancer risk. Br J Cancer 2006; 95:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/99\">",
"      Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990; 10:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/100\">",
"      Ahonen MH, Tenkanen L, Teppo L, et al. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000; 11:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/101\">",
"      Tuohimaa P, Tenkanen L, Ahonen M, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004; 108:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/102\">",
"      Mucci LA, Spiegelman D. Vitamin D and prostate cancer risk--a less sunny outlook? J Natl Cancer Inst 2008; 100:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/103\">",
"      Ahn J, Peters U, Albanes D, et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 2008; 100:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/104\">",
"      Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Allen NE, et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/105\">",
"      Roddam AW, Allen NE, Appleby P, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008; 149:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/106\">",
"      Hsing AW, Deng J, Sesterhenn IA, et al. Body size and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 2000; 9:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/107\">",
"      Hsing AW, Chua S Jr, Gao YT, et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 2001; 93:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/108\">",
"      Hsing AW, Gao YT, Chua S Jr, et al. Insulin resistance and prostate cancer risk. J Natl Cancer Inst 2003; 95:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/109\">",
"      Albanes D, Weinstein SJ, Wright ME, et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst 2009; 101:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/110\">",
"      Hubbard JS, Rohrmann S, Landis PK, et al. Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology 2004; 63:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/111\">",
"      Stewart SB, Freedland SJ. Influence of obesity on the incidence and treatment of genitourinary malignancies. Urol Oncol 2011; 29:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/112\">",
"      MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006; 17:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/113\">",
"      Wright ME, Chang SC, Schatzkin A, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007; 109:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/114\">",
"      Gong Z, Neuhouser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006; 15:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/115\">",
"      Rodriguez C, Freedland SJ, Deka A, et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2007; 16:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/116\">",
"      Su LJ, Arab L, Steck SE, et al. Obesity and prostate cancer aggressiveness among African and Caucasian Americans in a population-based study. Cancer Epidemiol Biomarkers Prev 2011; 20:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/117\">",
"      Giovannucci EL, Liu Y, Leitzmann MF, et al. A prospective study of physical activity and incident and fatal prostate cancer. Arch Intern Med 2005; 165:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/118\">",
"      Giovannucci EL. Author reply. Arch Intern Med 2005; 1675:2539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/119\">",
"      Platz EA, Leitzmann MF, Michaud DS, et al. Interrelation of energy intake, body size, and physical activity with prostate cancer in a large prospective cohort study. Cancer Res 2003; 63:8542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/120\">",
"      Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 2002; 13:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/121\">",
"      Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002; 60:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/122\">",
"      Sutcliffe S, Giovannucci E, Alderete JF, et al. Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/123\">",
"      Stark JR, Judson G, Alderete JF, et al. Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study. J Natl Cancer Inst 2009; 101:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/124\">",
"      Schlaberg R, Choe DJ, Brown KR, et al. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc Natl Acad Sci U S A 2009; 106:16351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/125\">",
"      Smith RA. Contamination of clinical specimens with MLV-encoding nucleic acids: implications for XMRV and other candidate human retroviruses. Retrovirology 2010; 7:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/126\">",
"      Alberts B. Editorial Expression of Concern. Science 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/127\">",
"      Paprotka T, Delviks-Frankenberry KA, Cing&ouml;z O, et al. Recombinant origin of the retrovirus XMRV. Science 2011; 333:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/128\">",
"      Zafar MB, Terris MK. Prostate cancer detection in veterans with a history of Agent Orange exposure. J Urol 2001; 166:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/129\">",
"      Shah SR, Freedland SJ, Aronson WJ, et al. Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomy. BJU Int 2009; 103:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/130\">",
"      Kane CJ, Im R, Amling CL, et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology 2010; 76:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/131\">",
"      Giri VN, Cassidy AE, Beebe-Dimmer J, et al. Association between Agent Orange and prostate cancer: a pilot case-control study. Urology 2004; 63:757.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine: Veterans and Agent Orange, Update 2000, National Academy Press, Washington DC 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/133\">",
"      Pavuk M, Michalek JE, Ketchum NS. Prostate cancer in US Air Force veterans of the Vietnam war. J Expo Sci Environ Epidemiol 2006; 16:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/134\">",
"      Chamie K, DeVere White RW, Lee D, et al. Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer. Cancer 2008; 113:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/135\">",
"      Multigner L, Ndong JR, Giusti A, et al. Chlordecone exposure and risk of prostate cancer. J Clin Oncol 2010; 28:3457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/136\">",
"      Jacobs EJ, Rodriguez C, Mondul AM, et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005; 97:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/137\">",
"      Dasgupta K, Di Cesar D, Ghosn J, et al. Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J 2006; 12:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/138\">",
"      Perron L, Bairati I, Moore L, Meyer F. Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 2003; 106:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/139\">",
"      Salinas CA, Kwon EM, FitzGerald LM, et al. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol 2010; 172:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/140\">",
"      Coogan PF, Rosenberg L, Palmer JR, et al. Statin use and the risk of breast and prostate cancer. Epidemiology 2002; 13:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/141\">",
"      Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008; 123:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/142\">",
"      Platz EA, Leitzmann MF, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/143\">",
"      Farwell WR, D'Avolio LW, Scranton RE, et al. Statins and prostate cancer diagnosis and grade in a veterans population. J Natl Cancer Inst 2011; 103:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/144\">",
"      Giovannucci E, Tosteson TD, Speizer FE, et al. A retrospective cohort study of vasectomy and prostate cancer in US men. JAMA 1993; 269:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/145\">",
"      Rosenberg L, Palmer JR, Zauber AG, et al. Vasectomy and the risk of prostate cancer. Am J Epidemiol 1990; 132:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/146\">",
"      Stanford JL, Wicklund KG, McKnight B, et al. Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999; 8:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/147\">",
"      Cox B, Sneyd MJ, Paul C, et al. Vasectomy and risk of prostate cancer. JAMA 2002; 287:3110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/148\">",
"      Giles GG, Severi G, English DR, et al. Sexual factors and prostate cancer. BJU Int 2003; 92:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/149\">",
"      Leitzmann MF, Platz EA, Stampfer MJ, et al. Ejaculation frequency and subsequent risk of prostate cancer. JAMA 2004; 291:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/150\">",
"      Luscombe CJ, Fryer AA, French ME, et al. Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet 2001; 358:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/151\">",
"      Bodiwala D, Luscombe CJ, Liu S, et al. Prostate cancer risk and exposure to ultraviolet radiation: further support for the protective effect of sunlight. Cancer Lett 2003; 192:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/152\">",
"      John EM, Dreon DM, Koo J, Schwartz GG. Residential sunlight exposure is associated with a decreased risk of prostate cancer. J Steroid Biochem Mol Biol 2004; 89-90:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/153\">",
"      Tuohimaa P, Pukkala E, Sc&eacute;lo G, et al. Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: vitamin D as a possible explanation. Eur J Cancer 2007; 43:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/154\">",
"      Myles P, Evans S, Lophatananon A, et al. Diagnostic radiation procedures and risk of prostate cancer. Br J Cancer 2008; 98:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/155\">",
"      Hoffman KE, Hong TS, Zietman AL, Russell AH. External beam radiation treatment for rectal cancer is associated with a decrease in subsequent prostate cancer diagnosis. Cancer 2008; 112:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/156\">",
"      Birgisson H, P&aring;hlman L, Gunnarsson U, Glimelius B. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 2005; 23:6126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/157\">",
"      Willett CG, Zietman AL, Shipley WU, Coen JJ. The effect of pelvic radiation therapy on serum levels of prostate specific antigen. J Urol 1994; 151:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/158\">",
"      Zietman AL, Zehr EM, Shipley WU. The long-term effect on PSA values of incidental prostatic irradiation in patients with pelvic malignancies other than prostate cancer. Int J Radiat Oncol Biol Phys 1999; 43:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/52/31562/abstract/159\">",
"      Parekh DJ, Ankerst DP, Higgins BA, et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology 2006; 68:1152.",
"     </a>",
"    </li>",
"    <li>",
"     Online prostate cancer risk calculator. www.compass.fhcrc.org/edrnnci/bin/calculator/main.asp (Accessed on February 25, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6938 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.137.129.113-F0872C54B4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_52_31562=[""].join("\n");
var outline_f30_52_31562=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H41\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETHNICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENETIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Family studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genome-wide association studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetic environmental interaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      BRCA2 and BRCA1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20799858\">",
"      HOXB13",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21977486\">",
"      Lynch syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Animal fat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vegetables",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Soy intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26833126\">",
"      Coffee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Vitamin and mineral supplements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Multivitamins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Folic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Selenium and vitamin E",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Zinc",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Calcium and vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      HORMONE LEVELS AND OBESITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Sex hormones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Insulin and insulin-like growth factor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Physical activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      OTHER FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Infection and chronic inflammation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Prostatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Trichomonas vaginalis infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - XMRV virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12086944\">",
"      Environmental carcinogens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Agent Orange",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12086956\">",
"      - Chlordecone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Use of NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Vasectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Ejaculatory frequency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Ultraviolet light exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Diagnostic radiologic procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      EBRT for rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      USING RISK FACTORS TO ESTIMATE PROSTATE CANCER RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/6938\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6938|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/62/34798\" title=\"figure 1\">",
"      Incidence prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/47/39679\" title=\"figure 2\">",
"      SEER fast stats results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/37/44637\" title=\"figure 3\">",
"      Prostate cancer by race",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6938|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/19/41277\" title=\"table 1A\">",
"      TNM staging prostate CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/43/10941\" title=\"table 1B\">",
"      TNM group prostate CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41736?source=related_link\">",
"      Chemoprevention strategies in prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36101?source=related_link\">",
"      Clinical presentation and diagnosis of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=related_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/39/14970?source=related_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/52/24394?source=related_link\">",
"      Interpretation of prostate biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/9/30874?source=related_link\">",
"      Molecular biology of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22666?source=related_link\">",
"      NSAIDs (including aspirin): Role in prevention of cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/13/4314?source=related_link\">",
"      Overview of testosterone deficiency in elderly men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/55/38770?source=related_link\">",
"      Patient information: Prostate cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=related_link\">",
"      Screening for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10230?source=related_link\">",
"      Statins: Possible noncardiovascular benefits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_52_31563="Replacement fluid volume";
var content_f30_52_31563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Replacement fluid volume for patients with dehydration",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Weight",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fluid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;4 months",
"       </td>",
"       <td>",
"        &lt;5 kg",
"       </td>",
"       <td>",
"        200 to 400 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 to 12 months",
"       </td>",
"       <td>",
"        5 to 8 kg",
"       </td>",
"       <td>",
"        400 to 600 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 2 years",
"       </td>",
"       <td>",
"        8 to 11 kg",
"       </td>",
"       <td>",
"        600 to 800 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 to 4 years",
"       </td>",
"       <td>",
"        11 to 16 kg",
"       </td>",
"       <td>",
"        800 to 1200 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5 to 14 years",
"       </td>",
"       <td>",
"        16 to 30 kg",
"       </td>",
"       <td>",
"        1200 to 2200 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;14 years",
"       </td>",
"       <td>",
"        &gt;30 kg",
"       </td>",
"       <td>",
"        2200 to 4400 mL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    If weight is known, may administer 100 mL/kg. Ongoing losses, if severe, should be incorporated into replacement phase. Fluids should never be restricted. For infants &lt;6 months receiving standard oral rehydration solutions (ORS), provide an additional 100 to 200 mL of water; this is not needed for patients receiving hypo-osmolar ORS.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: World Health Organization. The treatment of diarrhea: A manual for physicians and other senior health workers - 4th revision. World Health Organization, Geneva 2005. Available at:",
"     <a href=\"file://whqlibdoc.who.int/publications/2005/9241593180.pdf\" target=\"_blank\">",
"      file://whqlibdoc.who.int/publications/2005/9241593180.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_52_31563=[""].join("\n");
var outline_f30_52_31563=null;
var title_f30_52_31564="Chronic diarrhea stool type";
var content_f30_52_31564=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common causes of chronic diarrhea classified by typical stool characteristics, irrespective of age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Watery diarrhea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Osmotic diarrhea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Functional diarrhea (sometimes)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Magnesium, phosphate, sulfate ingestion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Carbohydrate malabsorption (lactose intolerance, mucosal disease, congenital disaccharidase deficiencies)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Secretory diarrhea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Laxative abuse (nonosmotic laxatives)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bacterial toxins",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bile acid malabsorption (post cholecystecomy ileal)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Inflammatory bowel disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Autoimmune enteropathy (isolated or IPEX syndrome)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vasculitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Drugs and poisons",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Disordered motility (Hirshsprung's disease, pseudoobstruction)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Neuroendocrine tumors (gastrin, VIP, carcinoid, mastocytosis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Neoplasia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Addison's disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Epidemic secretory diarrhea (brainerd diarrhea)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Idiopathic secretory diarrhea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Congenital secretory diarrheas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Inflammatory diarrhea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inflammatory bowel disease (ulcerative colitis, Crohn's disease, microscopic [lymphocytic and collagenous] colitis, diverticulitis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Infectious diseases (ulcerating viral infections, enteric bacterial pathogens, parasites)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ischemic colitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Radiation colitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neoplasia (colon cancer, Lymphoma)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Fatty diarrhea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Malabsorption syndromes (mucosal diseases [eg, celiac], short-bowel syndrome, post-resection diarrhea, mesenteric ischemia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maldigestion (pancreatic insufficiency [eg, cystic fibrosis], bile acid deficiency)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Schiller, LR. Chronic diarrhea. Gastroenterology 2004; 127:287. Copyright &copy;2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_52_31564=[""].join("\n");
var outline_f30_52_31564=null;
var title_f30_52_31565="AAP followup schedule CDH";
var content_f30_52_31565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended schedule of follow-up for infants with congenital diaphragmatic hernia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Before discharge",
"      </td>",
"      <td class=\"subtitle1\">",
"       1-3 months after birth",
"      </td>",
"      <td class=\"subtitle1\">",
"       4-6 months after birth",
"      </td>",
"      <td class=\"subtitle1\">",
"       9-12 months after birth",
"      </td>",
"      <td class=\"subtitle1\">",
"       15-18 months after birth",
"      </td>",
"      <td class=\"subtitle1\">",
"       Annual through 16 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Weight, length, occipital-frontal circumference",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chest radiograph",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       If patched",
"      </td>",
"      <td>",
"       If patched",
"      </td>",
"      <td>",
"       If patched",
"      </td>",
"      <td>",
"       If patched",
"      </td>",
"      <td>",
"       If patched",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pulmonary function testing",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       If indicated",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       If indicated",
"      </td>",
"      <td>",
"       If indicated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Childhood immunizations",
"      </td>",
"      <td>",
"       As indicated throughout childhood",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       RSV prophylaxis",
"      </td>",
"      <td>",
"       RSV season during first 2 years after birth (if evidence of chronic lung disease)",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Echocardiogram and cardiology follow-up",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       If previously abnormal or if on supplemental oxygen",
"      </td>",
"      <td>",
"       If previously abnormal or if on supplemental oxygen",
"      </td>",
"      <td>",
"       If previously abnormal or if on supplemental oxygen",
"      </td>",
"      <td>",
"       If previously abnormal or if on supplemental oxygen",
"      </td>",
"      <td>",
"       If previously abnormal or if on supplemental oxygen",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Head computed tomography or MRI",
"      </td>",
"      <td>",
"       If (1) abnormal finding on head ultrasound; (2) seizures/abnormal neurologic findings*; or (3) ECMO or patch repair",
"      </td>",
"      <td>",
"       As indicated",
"      </td>",
"      <td>",
"       As indicated",
"      </td>",
"      <td>",
"       As indicated",
"      </td>",
"      <td>",
"       As indicated",
"      </td>",
"      <td>",
"       As indicated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hearing evaluation",
"      </td>",
"      <td>",
"       Auditory brainstem evoked response or otoacoustic emissions screen",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       Every 6 months to age 3 years, then annually to age 5 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Developmental screening evaluation",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Annually to age 5 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neurodevelopmental evaluation",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Annually to age 5 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Assessment for oral feeding problems",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       If oral feeding problems",
"      </td>",
"      <td>",
"       If oral feeding problems",
"      </td>",
"      <td>",
"       If oral feeding problems",
"      </td>",
"      <td>",
"       If oral feeding problems",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Upper gastrointestinal study, pH probe, and/or gastric scintiscan",
"      </td>",
"      <td>",
"       Consider for all patients",
"      </td>",
"      <td>",
"       If symptoms",
"      </td>",
"      <td>",
"       If symptoms",
"      </td>",
"      <td>",
"       Consider for all patients",
"      </td>",
"      <td>",
"       If symptoms",
"      </td>",
"      <td>",
"       If symptoms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Esophagoscopy",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       If symptoms",
"      </td>",
"      <td>",
"       If symptoms",
"      </td>",
"      <td>",
"       If symptoms or if abnormal gastrointestinal evaluations",
"      </td>",
"      <td>",
"       If symptoms",
"      </td>",
"      <td>",
"       If symptoms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Scoliosis and chest wall deformity screening (physical examination, chest radiograph, and/or computed tomography of the chest)",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The neurosensory tests performed and frequency of surveillance may differ among infants with CDH because of variability in neurologic, developmental, and physiologic impairments. Follow-up should be tailored to each infant.",
"    <div class=\"footnotes\">",
"     RSV: respiratory syncytial virus.",
"     <br>",
"      * Muscle weakness, hypotonia, hypertonia, or other abnormal neurologic sign or symptom.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lally KP, Engle W. Postdischarge follow-up of infants with congenital diaphragmatic hernia. Pediatrics 2008; 121:627. Copyright &copy; 2008 by the AAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_52_31565=[""].join("\n");
var outline_f30_52_31565=null;
var title_f30_52_31566="Thoracic aortic aneurysm in giant cell arteritis";
var content_f30_52_31566=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F72571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F72571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thoracic aortic aneurysm in giant cell arteritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomographic scan in a patient with giant cell arteritis who developed an aortic aneurysm with dissection six years after the original diagnosis of arteritis by temporal artery biopsy. The aneurysm extended from the enlarged thoracic aorta (arrow) into the abdomen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gene G Hunder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_52_31566=[""].join("\n");
var outline_f30_52_31566=null;
var title_f30_52_31567="DIP osteoarthritis xray";
var content_f30_52_31567=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osteoarthritis of the distal interphalangeal (DIP) joints",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 315px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain film demonstrates complete loss of the articular cartilage at all four DIP joints, large osteophytes, and ankylosis of the DIP joint of the middle finger.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_52_31567=[""].join("\n");
var outline_f30_52_31567=null;
